[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 398
1. Kubba LA, McCluggage WG, Liu J, Malpica A, Euscher ED, Silva EG, Deavers MT: Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol; 2008 Apr;21(4):485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In most of the positive cases, staining was focal, but in one endometrioid adenocarcinoma in the tissue microarray and in one serous and one clear cell carcinoma in the whole tissue sections, there was diffuse positivity.
  • Although TTF-1 nuclear expression is generally considered to be a relatively specific marker for lung and thyroid neoplasms, the occasional immunoreactivity of ovarian carcinomas should be considered in the evaluation of neoplasms of unknown primary origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246044.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TTF1 protein, human
  •  go-up   go-down


2. Peter S, Eltoum I, Eloubeidi MA: EUS-guided FNA of peritoneal carcinomatosis in patients with unknown primary malignancy. Gastrointest Endosc; 2009 Dec;70(6):1266-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided FNA of peritoneal carcinomatosis in patients with unknown primary malignancy.
  • OBJECTIVE: We aimed to determine the feasibility and success in sampling lesions in the peritoneum suspicious for carcinomatosis without a primary source.
  • Two patients had metastatic adenocarcinoma, 1 patient had lymphoma, and 1 patient had metastatic breast carcinoma.
  • In the setting of an unknown primary cancer, EUS-guided FNA facilitates acquisition of tissues for treatment allocation, thus avoiding the need for laparoscopy or laparotomy.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma / pathology. Endosonography. Neoplasms, Unknown Primary / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2011 Jan;73(1):188-9 [21184887.001]
  • (PMID = 19640520.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Nguyen MD, Plasil B, Wen P, Frankel WL: Mucin profiles in signet-ring cell carcinoma. Arch Pathol Lab Med; 2006 Jun;130(6):799-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Signet-ring cell carcinoma (SRCC) is a poorly differentiated mucin-producing adenocarcinoma that may arise from many different organs, but all SRCCs share identical morphology.
  • OBJECTIVE: To identify mucin profiles of primary and metastatic SRCCs using immunohistochemistry to determine whether mucin staining could help distinguish sites of origin.
  • DESIGN: Forty-seven SRCCs, including 38 primary (21 stomach, 11 colorectum, and 6 breast) and 9 metastases from these primary sites were retrieved from archival files.
  • Mucin profiling may be useful to identify the origin of a metastatic SRCC of unknown primary.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / metabolism. Immunohistochemistry / methods. Mucins / metabolism. Neoplasms, Unknown Primary / diagnosis


Advertisement
4. Maitra M, Wang Y, Gerard RD, Mendelson CR, Garcia CK: Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem; 2010 Jul 16;285(29):22103-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rare heterozygous mutations in the gene encoding surfactant protein A2 (SP-A2, SFTPA2) are associated with adult-onset pulmonary fibrosis and adenocarcinoma of the lung.
  • The pathogenic mechanism of the mutant proteins is unknown.
  • Here we analyze all common and rare variants of the surfactant protein A2, SP-A2, in both A549 cells and in primary type II alveolar epithelial cells.

  • Genetic Alliance. consumer health - Pulmonary Fibrosis.
  • MedlinePlus Health Information. consumer health - Pulmonary Fibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2001 May;129(1):109-27 [11369537.001]
  • [Cites] Mol Cell. 1998 Oct;2(4):505-14 [9809072.001]
  • [Cites] Am J Respir Crit Care Med. 2002 May 1;165(9):1322-8 [11991887.001]
  • [Cites] Biochim Biophys Acta. 1998 Nov 19;1408(2-3):296-302 [9813377.001]
  • [Cites] Biochim Biophys Acta. 1998 Nov 19;1408(2-3):312-22 [9813381.001]
  • [Cites] Mol Med. 1999 Apr;5(4):224-31 [10448644.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):58-68 [15630429.001]
  • [Cites] Annu Rev Physiol. 2005;67:663-96 [15709974.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Jun;32(6):521-30 [15778495.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2656-64 [16200199.001]
  • [Cites] Respirology. 2006 Jan;11 Suppl:S12-5 [16423262.001]
  • [Cites] J Cell Biol. 2006 Jan 30;172(3):395-407 [16449190.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1317-26 [17392301.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7 [17460043.001]
  • [Cites] Biochem J. 2007 Sep 15;406(3):479-89 [17542781.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L720-9 [17586700.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Oct 1;178(7):729-37 [18635888.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Oct 15;178(8):838-46 [18635891.001]
  • [Cites] Am J Hum Genet. 2009 Jan;84(1):52-9 [19100526.001]
  • [Cites] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009 Dec;23(12):1409-12 [20073298.001]
  • [Cites] J Cell Sci. 2003 Feb 15;116(Pt 4):683-92 [12538769.001]
  • [Cites] Infect Immun. 2003 Mar;71(3):1306-15 [12595446.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43254-60 [12913002.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52739-46 [14525980.001]
  • [Cites] Biochemistry. 2004 Apr 13;43(14):4227-39 [15065867.001]
  • [Cites] Br J Cancer. 2004 Aug;91 Suppl 2:S3-10 [15340372.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):1889-92 [6952238.001]
  • [Cites] Am J Physiol. 1989 Dec;257(6 Pt 1):L421-9 [2610270.001]
  • [Cites] Am J Physiol. 1994 Apr;266(4 Pt 1):L367-74 [8179013.001]
  • [Cites] N Engl J Med. 2002 Dec 26;347(26):2141-8 [12501227.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9594-9 [8790375.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Dec;17(6):672-82 [9409554.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Aug;19(2):202-9 [9698591.001]
  • [Cites] Anal Biochem. 1978 Nov;91(1):350-3 [9762117.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Oct;19(4):613-21 [9761758.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):707-12 [11901176.001]
  • (PMID = 20466729.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL093096; United States / NHLBI NIH HHS / HL / HL050022; United States / NHLBI NIH HHS / HL / R37 HL050022; United States / NHLBI NIH HHS / HL / R01 HL093096; United States / NHLBI NIH HHS / HL / R01 HL050022
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Extracts; 0 / Detergents; 0 / Leupeptins; 0 / Mutant Proteins; 0 / Pulmonary Surfactant-Associated Protein A; 0 / SFTPA1 protein, human; 0 / SFTPA2 protein, human; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde
  • [Other-IDs] NLM/ PMC2903395
  •  go-up   go-down


5. Boscolo-Rizzo P, Gava A, Da Mosto MC: Carcinoma metastatic to cervical lymph nodes from an occult primary tumor: the outcome after combined-modality therapy. Ann Surg Oncol; 2007 May;14(5):1575-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma metastatic to cervical lymph nodes from an occult primary tumor: the outcome after combined-modality therapy.
  • BACKGROUND: The aim of this retrospective analysis was to analyze the results of treatment of patients with cervical node metastases from carcinoma of occult primary with a policy including neck dissection and postoperative comprehensive radiotherapy.
  • The actuarial rate of developing head and neck primary tumors at 5 years was 8.9% (95% CI, 2.6%-15.2%).
  • A total of 32 (35.6%) had died from causes related to their primary disease.
  • CONCLUSIONS: Our study seems to support the use of combined-modality therapy in patients with neck metastases from carcinoma of occult primary.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508250.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Braeuninger S, Mawrin C, Malfertheiner P, Schildhaus HU, Seiler C, Dietzmann K, Lins H: Gastric adenocarcinoma with leptomeningeal carcinomatosis as the presenting manifestation: an autopsy case report. Eur J Gastroenterol Hepatol; 2005 May;17(5):577-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma with leptomeningeal carcinomatosis as the presenting manifestation: an autopsy case report.
  • Herein, we report a case of leptomeningeal carcinomatosis as the initial manifestation of a previously asymptomatic gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Meningeal Neoplasms / secondary. Neoplasms, Unknown Primary / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827450.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Chao TC, Chao HH, Jan YY, Chen MF: Perforation through small bowel malignant tumors. J Gastrointest Surg; 2005 Mar;9(3):430-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathology included lymphoma (seven patients), leiomyosarcoma (two patients), gastrointestinal stromal tumor (one patient), adenocarcinoma (one patient), metastatic carcinomas with unknown primary tumor (four patients), metastatic adenocarcinoma from the lung (one patient), and metastatic carcinomas from the hypopharynx (one patient), cervix (one patient), and lung (one patient).
  • Resection of a segment of perforated bowel with primary anastomosis was performed in 16 patients, wedge resection of perforated lesion with plication in two patients, and loop ileostomy in one patient.
  • Seven patients died from the primary malignancy at a median follow-up of 6.5 months (range, 5 months to 1 year 9 months) after surgery.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1988 Feb;6(2):291-6 [3339395.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):732-40 [453945.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2157-60 [9951884.001]
  • [Cites] Acta Chir Scand. 1989 Nov-Dec;155(11-12):593-9 [2618515.001]
  • [Cites] Acta Radiol. 1998 Jan;39(1):52-6 [9498870.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Surgery. 2000 Feb;127(2):178-84 [10686983.001]
  • [Cites] Ann Surg. 1996 Jul;224(1):10-8 [8678610.001]
  • [Cites] J Surg Oncol. 1992 Dec;51(4):287-91 [1434663.001]
  • [Cites] Ann Surg. 1980;192(4):581-6 [7425698.001]
  • [Cites] Surgery. 1982 Oct;92(4):605-9 [6981865.001]
  • [Cites] Dis Colon Rectum. 1983 May;26(5):323-6 [6653291.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1999 Feb;66(1):37-40 [10097589.001]
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Arch Surg. 1989 Jul;124(7):830-2 [2742484.001]
  • [Cites] Am Surg. 1989 Jul;55(7):408-12 [2787134.001]
  • [Cites] Surg Today. 2001;31(4):358-62 [11321350.001]
  • [Cites] J Am Coll Surg. 1997 Sep;185(3):250-4 [9291402.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1884-7 [10406253.001]
  • [Cites] J Surg Oncol. 1989 Aug;41(4):219-21 [2666757.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):355-8 [3565679.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] J Clin Gastroenterol. 2000 Apr;30(3):289-93 [10777190.001]
  • [Cites] Cancer. 1978 May;41(5):1984-9 [348299.001]
  • [Cites] Ann Surg. 1981 Jan;193(1):67-9 [7458451.001]
  • (PMID = 15749607.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Wang XW, Ni DF: [Investigation of the characters of cervical lymph node metastases of primary malignant tumor beyond head and neck]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Jun;42(6):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of the characters of cervical lymph node metastases of primary malignant tumor beyond head and neck].
  • OBJECTIVE: To investigate the characters of cervical lymph node metastases of primary tumors beyond head and neck.
  • RESULTS: The primary sites of these 77 cases of malignant tumor consisted of lung, stomach, esophagus, galactophore, colon, mediastinum, ovary, uterus, pancreas, liver, mesentery, adrenal gland and rectum.
  • The proportion of the metastases of malignant tumor from primary site beyond head and neck in each region was 2.1% in LEVEL I, 3.7% in LEVEL III, 14.3% in LEVEL IV, 70.8% in LEVEL V.
  • Among the cervical lymph node metastases of primary tumor beyond head and neck, 51.9% were low-grade adenocarcinoma, 15.6% were medial-grade adenocarcinoma, 11.7% were low-grade squamous cell carcinoma, 10.4% were medial-grade squamous carcinoma.
  • The metastases from primary sites beyond head and neck usually focus on LEVEL V (81.8%), especially in the left.
  • And the primary tumors beyond head and neck metastasis in this region were more than the tumors from head and neck locally.
  • The histological type of the primary tumors were frequently low-medial grade carcinomas.
  • [MeSH-major] Lymph Nodes. Lymphatic Metastasis. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702413.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Dennis JL, Oien KA: Hunting the primary: novel strategies for defining the origin of tumours. J Pathol; 2005 Jan;205(2):236-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hunting the primary: novel strategies for defining the origin of tumours.
  • Finally, the diagnostic problem of adenocarcinomas that present as metastases of unknown origin is reviewed, and it is demonstrated how integration of expression profiling techniques promises to throw new light on this important clinical challenge.
  • [MeSH-major] Gene Expression Profiling / methods. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Computational Biology / methods. Humans. Oligonucleotide Array Sequence Analysis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15641019.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 110
  •  go-up   go-down


10. Gómez-Puerta JA, Cervera R, Espinosa G, Aguiló S, Bucciarelli S, Ramos-Casals M, Ingelmo M, Asherson RA, Font J: Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum; 2006 Apr;35(5):322-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regarding solid tumors, renal cell carcinoma was diagnosed in 7 (6%) patients, primary tumor with unknown origin in 7 (6%), lung adenocarcinoma in 6 (5%), breast carcinoma in 6 (5%), and melanoma in 6 (5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616155.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid
  • [Number-of-references] 107
  •  go-up   go-down


11. Ishiguro T, Fu Y, Sadatou T, Shimokawa N, Shibamoto K: [Detection of unknown primary tumor in a patient with cerebellar metastasis using FDG PET-CT: case report]. No Shinkei Geka; 2006 Oct;34(10):1027-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of unknown primary tumor in a patient with cerebellar metastasis using FDG PET-CT: case report].
  • Identification of unknown primary tumors in patients with brain metastasis is a continued diagnostic challenge.
  • We report a case to show that FDG PET-CT was able to detect an unknown primary tumor.
  • The histological diagnosis was adenocarcinoma metastasis.
  • In conclusion, from now on, FDG PET-CT will be considered as the first diagnostic process for patients presenting brain metastasis with an unknown primary tumor.
  • [MeSH-major] Cerebellar Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052015.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Roblick UJ, Bader FG, Lenander C, Hellman U, Zimmermann K, Becker S, Ost A, Alaiya A, Bruch HP, Keller R, Mirow L, Franzén B, Ried T, Auer G, Habermann JK: Undifferentiated pelvic adenocarcinomas: diagnostic potential of protein profiling and multivariate analysis. Int J Colorectal Dis; 2008 May;23(5):483-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A poorly differentiated adenocarcinoma of unknown origin located in the pelvis, infiltrating the sigmoid colon as well as the ovary, served as a model to evaluate our proteomic approach.
  • Qualitative and quantitative patterns were recorded and compared to the tumor of unknown origin.
  • RESULTS: Over 89% of the unknown tumor sample spots could be matched with the colon standard gel, whereas only 63% of the spots could be matched with the ovarian standard.
  • In addition, principal component analysis impressively displayed the clustering of the unknown case within the colon cancer samples, whereas this case did not cluster at all within the group of ovarian adenocarcinomas.
  • CONCLUSION: These results show that 2-DE protein expression profiling combined with principal component analysis is a sensitive method for diagnosing undifferentiated adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / secondary. Cell Differentiation. Colonic Neoplasms / secondary. Neoplasm Proteins / analysis. Neoplasms, Unknown Primary / diagnosis. Ovarian Neoplasms / secondary. Pelvic Neoplasms / diagnosis. Proteomics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):769-75 [17131332.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5243-50 [14500354.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):909-13 [8611405.001]
  • [Cites] J Biol Chem. 1989 Mar 25;264(9):5269-82 [2925692.001]
  • [Cites] Hum Pathol. 1998 May;29(5):491-7 [9596273.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):852-5 [7543441.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4111-7 [9307301.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):9-16 [14695313.001]
  • [Cites] Mod Pathol. 1996 Nov;9(11):1040-4 [8933513.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12 (24):7359-68 [17189408.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1632-8 [8932346.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3638-46 [10612291.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):426-9 [8729984.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):678-83 [9398045.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1994 Feb;40(1):57-75 [8003936.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2655-60 [11135228.001]
  • [Cites] Electrophoresis. 1994 Mar-Apr;15(3-4):382-90 [7914486.001]
  • [Cites] Int J Cancer. 1996 Oct 21;69(5):408-14 [8900376.001]
  • [Cites] Electrophoresis. 1997 Mar-Apr;18(3-4):582-7 [9150945.001]
  • [Cites] Electrophoresis. 1995 Jul;16(7):1087-9 [7498151.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):909-16 [10506443.001]
  • [Cites] FEBS Lett. 1999 Nov 26;462(1-2):129-34 [10580105.001]
  • [Cites] Cell Mol Life Sci. 2004 May;61(10):1246-55 [15141310.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):731-6 [10797298.001]
  • [Cites] Anal Cell Pathol. 2000;21(1):1-9 [11254220.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34 [14623978.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):895-9 [11948469.001]
  • [Cites] J Clin Microbiol. 1991 Mar;29(3):648-9 [2037688.001]
  • [Cites] Cell Mol Life Sci. 2001 Feb;58(2):307-11 [11289312.001]
  • [Cites] Eur J Biochem. 2000 Aug;267(15):4713-9 [10903504.001]
  • [Cites] Acta Oncol. 2007;46(5):592-601 [17562435.001]
  • (PMID = 18293003.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


13. Fizazi K: Treatment of patients with specific subsets of carcinoma of an unknown primary site. Ann Oncol; 2006 Sep;17 Suppl 10:x177-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with specific subsets of carcinoma of an unknown primary site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018719.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 15
  •  go-up   go-down


14. Yoshida K, Kobayashi N, Kurai M, Hyogotani A, Kondo R, Amano J: A subtotal sternectomy successfully reconstructed with composix mesh. Ann Thorac Cardiovasc Surg; 2006 Dec;12(6):420-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / surgery. Bone Neoplasms / surgery. Sternum / surgery. Surgical Mesh. Thoracic Neoplasms / surgery. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Aged. Humans. Male. Neoplasms, Unknown Primary / surgery. Prostatic Neoplasms / pathology. Surgical Flaps. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228281.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Rupasinghe J, Butler E: Progressive ataxic gait disorder. J Clin Neurosci; 2007 Feb;14(2):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the case reported herein, a secondary tumour with unknown primary was suggested after detection of a pathological lymph node in the right axilla by a positron emission tomography scan.
  • Microscopic examination of the ultrasound-guided resected tissue was a poorly differentiated adenocarcinoma strongly positive for the C-ERB 2 oncoprotein.
  • [MeSH-major] Adenocarcinoma / complications. Gait Ataxia / etiology. Lymphatic Metastasis / pathology. Neoplasms, Unknown Primary / complications. Paraneoplastic Cerebellar Degeneration / etiology

  • MedlinePlus Health Information. consumer health - Walking Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17161290.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


16. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
  • Distinction of primary ovarian epithelial tumors from metastatic adenocarcinomas is challenging for tumors exhibiting mucinous, endometrioid, or mixed endometrioid/mucinous differentiation.
  • Most endocervical adenocarcinomas exhibit mucinous and/or endometrioid differentiation; they infrequently metastasize to the ovaries but may simulate primary ovarian tumors [both atypical proliferative (borderline) and carcinoma].
  • The performance of this expression pattern for identifying metastatic endocervical adenocarcinomas in the ovaries among primary ovarian tumors and other metastatic adenocarcinomas having mucinous and/or endometrioid/endometrioidlike differentiation has not been evaluated.
  • Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
  • Mean and median expression values for HPV-positive endocervical adenocarcinomas (99%, 100%; range 90% to 100%) were substantially higher than those for primary ovarian mucinous (5%, 0%; range 0% to 70%) and endometrioid (20%, 10%; range 0% to 100%) tumors, HPV-unrelated endocervical adenocarcinomas (0%, 0%; range 0% to 60%), metastatic adenocarcinomas of unknown origin (11%, 0%; range 0% to 30%), and adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin (40%, 35%; range 0% to 90%); only the 15 HPV-positive endocervical adenocarcinomas and 6 other tumors had values of 80% or greater.
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism


17. Villaret AB, Piazza C, Peretti G, Calabrese L, Ansarin M, Chiesa F, Pellini R, Spriano G, Nicolai P: Multicentric prospective study on the prevalence of sublevel IIb metastases in head and neck cancer. Arch Otolaryngol Head Neck Surg; 2007 Sep;133(9):897-903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the prevalence of sublevel IIB lymph node (LN) metastases for head and neck primary tumors in a large cohort of patients.
  • PATIENTS: Between 2003 and 2005, 297 patients (male to female ratio, 3.5:1; mean age, 58.8 years [range, 18-89 years]) affected by head and neck cancer were treated by surgery on the primary tumor and/or the neck.
  • Primary site distribution included the following: oral cavity in 111 patients, larynx in 92, oropharynx in 32, thyroid gland in 22, skin of the lateral face or scalp in 16, hypopharynx in 11, unknown primary in 7, and parotid gland in 6.
  • INTERVENTIONS: All patients underwent unilateral or bilateral neck dissection (ND) with therapeutic or elective intent according to the primary site and clinical T (cT) and clinical N (cN) status.
  • The influence of several factors (institution in which the surgical procedure was performed, sex of the patient, site of primary, histotype, pathologic T [pT] status, cN status, lower level involved in the neck together with sublevel IIB, association with sublevel IIA metastasis, ipsilateral number of involved levels, and previous surgical treatment limited on the primary site) on the prevalence of sublevel IIB metastasis was statistically evaluated by the Pearson chi(2) test or Fisher exact test.
  • Tumor histologic type in the sublevel IIB+ population was squamous cell carcinoma in 80%, papillary carcinoma in 8%, melanoma in 8%, and adenocarcinoma in 4%.
  • The chi(2) test showed a significantly higher risk for LN metastases at sublevel IIB in patients affected by parotid gland primary tumors (33%), tumors of the skin or scalp (25%), unknown primary tumors (14%), and cancers of the oral cavity (10%) (P = .02) and in those clinically staged as cN+ (P < .001).
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cross-Sectional Studies. Female. Humans. Lymph Node Excision. Male. Melanoma / epidemiology. Melanoma / pathology. Melanoma / surgery. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875856.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


18. Gopaldas R, Kunasani R, Plymyer MR, Bloch RS: Hepatoid malignancy of unknown origin--a diagnostic conundrum: review of literature and case report of collision with adenocarcinoma. Surg Oncol; 2005 Jul;14(1):11-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid malignancy of unknown origin--a diagnostic conundrum: review of literature and case report of collision with adenocarcinoma.
  • Based on a review of literature, we discuss the guidelines for differentiating these tumors and utilize these criteria to differentiate these tumors irrespective of their primary tissue of origin.
  • We also describe an unusual case of hepatoid variant of primary peritoneal yolk sac tumor presenting with extensive carcinomatosis and as a collision with two synchronous primary colonic adenocarcinomas, neither of which has been reported to our knowledge to date, thereby falsely mimicking metastatic dedifferentiated colonic adenocarcinoma.
  • In the absence of a primary identifiable liver disease, this is consistent with either hepatoid variant of primary yolk sac tumor or hepatoid carcinoma arising from the peritoneum.
  • The right colectomy specimen revealed two mucosal ulcers consistent with colonic adenocarcinoma abutting two large tumor nodules on the serosal surface.
  • With no evidence of yolk sac component within the colonic tumor or in the draining lymphatics, this essentially excludes the commonly observed metastatic dedifferentiation (opisthoplasia) of adenocarcinoma to primitive forms (also known as combination tumors).
  • This unusual presentation of two entirely different primary malignancies in close proximity is defined as "collision tumor".
  • This is the first reported case of collision tumors involving dual colonic and primary peritoneal hepatoid-YST.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Endodermal Sinus Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Peritoneal Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15777886.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 52
  •  go-up   go-down


19. DeMartini W, Lehman C, Partridge S: Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications. Acad Radiol; 2008 Apr;15(4):408-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Breast MRI has been shown in multiple studies to be advantageous for screening patients at high risk, evaluating patients with a new breast cancer diagnosis, monitoring treatment response in patients undergoing neoadjuvant chemotherapy and evaluating patients with metastatic axillary adenocarcinoma and unknown primary site.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342764.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 72
  •  go-up   go-down


20. Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K: Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol; 2007 Aug;128(2):255-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic adenocarcinoma of unknown primary site, eg, to lymph nodes, liver, or lung, may originate from many organs.
  • A high prevalence of cytokeratin (CK)17 expression in pancreaticobiliary adenocarcinoma was reported, and preliminary data indicate infrequent or missing expression in gastric adenocarcinoma.
  • CK17 expression was as follows: pancreatic, 88%; bile duct, 59%; esophageal, 30%; distal gastric, 28%; gastric cardiac, 27%; and colorectal adenocarcinoma, 6%.
  • These differences were statistically significant for all tumor types except in comparisons of esophageal, cardiac, and distal gastric adenocarcinoma.
  • However, in individual cases of adenocarcinoma of unknown primary site, CK17 results alone are insufficient to differentiate the analyzed tumor entities.
  • [MeSH-major] Adenocarcinoma / chemistry. Bile Duct Neoplasms / chemistry. Gastrointestinal Neoplasms / chemistry. Keratin-17 / analysis. Pancreatic Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638659.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-17
  •  go-up   go-down


21. Italiano A, Cortot AB, Ilie M, Martel-Planche G, Fabas T, Pop D, Mouroux J, Hofman V, Hofman P, Pedeutour F: EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer; 2009 Nov 15;125(10):2479-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.
  • Although epidermal growth factor receptor (EGFR)-targeted therapies have emerged as a promising therapeutic approach in patients with advanced typical NSCLC such as adenocarcinoma, the potential clinical activity of these drugs in lung SC is still unknown.
  • EGFR protein expression, EGFR gene copy number, EGFR mutational status and KRAS mutational status were assessed in a series of 22 consecutive cases of primary lung SC.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2011 Feb 1;128(3):732-5; author reply 736 [20309946.001]
  • (PMID = 19681124.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


22. Ethunandan M, Pratt CA, Morrison A, Anand R, Macpherson DW, Wilson AW: Multiple synchronous and metachronous neoplasms of the parotid gland: the Chichester experience. Br J Oral Maxillofac Surg; 2006 Oct;44(5):397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence and implications of multiple synchronous and metachronous tumours remains relatively unknown.
  • We reviewed the case notes of 606 patients who had parotidectomies for neoplastic lesions over a 30 year period and identified 30 patients (5%) with multiple primary tumours.
  • [MeSH-major] Adenolymphoma / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Second Primary / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenoma, Oxyphilic / pathology. Adenoma, Pleomorphic / pathology. Adult. Aged. Aged, 80 and over. England. Female. Humans. Lipoma / pathology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16207507.001).
  • [ISSN] 0266-4356
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


23. Hazeki N, Kobayashi K, Yamamoto M, Kotani Y, Kondo T, Nishimura Y: [Pulmonary tumor thrombotic microangiopathy associated with cancer of unknown origin]. Nihon Kokyuki Gakkai Zasshi; 2009 Nov;47(11):1030-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary tumor thrombotic microangiopathy associated with cancer of unknown origin].
  • An autopsy showed pulmonary embolism and swollen abdominal lymph nodes consisting of metastatic signet-ring cell carcinoma and poorly differentiated adenocarcinoma.
  • In spite of various immunohistological staining procedure, we could not find out the primary lesion of this cancer.
  • [MeSH-major] Neoplasms, Unknown Primary. Neoplastic Cells, Circulating / pathology. Pulmonary Embolism / etiology. Thrombotic Microangiopathies / etiology
  • [MeSH-minor] Adenocarcinoma / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994600.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Shaw PH, Adams R, Jordan C, Crosby TD: A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clin Oncol (R Coll Radiol); 2007 Feb;19(1):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.
  • AIMS: Carcinoma of unknown primary (CUP) is a common encounter in oncological practice and represents 2.0-6.0% of all invasive malignancies.
  • Evidence to support particular therapeutic strategies in this patient population is scarce, and empirical therapies are frequently derived from research on patients where the primary tumour site is known.
  • MATERIALS AND METHODS: This retrospective study reviewed the management of all patients recorded to have a diagnosis of CUP in a single cancer centre over a period of 12 months.
  • Health records were reviewed documenting the CUP subtype, the investigations carried out both in the referring cancer unit and subsequently at the cancer centre and the recommended treatment (type and regimen), together with survival.
  • RESULTS: One hundred and sixty-six patients were recorded to have a diagnosis of CUP, representing 3.7% of all referrals to the cancer centre.
  • The three most common CUP subgroups were CUP-liver/multiple sites (25.0%), CUP-bone (21.0%) and CUP-brain (16.0%).
  • Even within a single subtype, 41 patients with CUP-liver/multiple sites underwent a total of 19 different investigations before any treatment being given.
  • Nine different 5-fluorouracil-containing regimens were used in 11 patients treated with chemotherapy for CUP-liver.
  • CONCLUSIONS: The appropriate management of patients with CUP is unclear and this study revealed a high degree of variation in clinical practice.
  • This area is in urgent need of clinical research to ensure that the treatment of CUP is evidence based.
  • Therapeutic progress will be facilitated by designating a clinical lead for CUP in each clinical network.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305260.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR: Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res; 2005 Dec 15;11(24 Pt 1):8773-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: X-ray therapy (XRT) remains one of the major modalities used to treat patients diagnosed with locally advanced pancreatic adenocarcinoma.
  • However, the effect of XRT on metastatic tumors outside the field of irradiation (abscopal effect) remains largely unknown.
  • This chemoradiation regimen was chosen based on our molecular analysis of pancreatic adenocarcinoma.
  • CONCLUSIONS: These results have implications in the rational design of treatment paradigms for pancreatic cancer where metastatic disease remains the primary cause of patient morbidity and abscopal effects in tumors outside the field of irradiation may affect tumor response.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclooxygenase Inhibitors / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 3.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Lead, elemental .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361565.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA101955-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Ki-67 Antigen; 0 / Pyrazoles; 0 / RNA, Messenger; 0 / Sulfonamides; 0W860991D6 / Deoxycytidine; 2P299V784P / Lead; 6804DJ8Z9U / Capecitabine; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 3.1.3.5 / 5'-Nucleotidase; JCX84Q7J1L / Celecoxib; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Caballero Gullón L, Borrego Dorado I, Vázquez Albertino R: [A colon adenocarcinoma and a pharyngeal carcinoma incidentally detected by means of (18)F-FDG PET in a patient diagnosed of lung cancer]. Rev Esp Med Nucl; 2010 Jan-Feb;29(1):29-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A colon adenocarcinoma and a pharyngeal carcinoma incidentally detected by means of (18)F-FDG PET in a patient diagnosed of lung cancer].
  • [Transliterated title] Adenocarcinoma de colon y carcinoma faríngeo detectados incidentalmente mediante (18)F-FDG PET en paciente diagnosticado de cáncer de pulmón.
  • It is also especially useful in patients with solitary pulmonary nodule, bronchogenic carcinoma, head and neck cancer, colon cancer, tumors of unknown origin, lymphomas, etc.
  • Its capacity to detect previously unsuspected second or third primary tumors has also been demonstrated.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Lung Neoplasms / radiography. Neoplasms, Multiple Primary / radionuclide imaging. Pharyngeal Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 19969392.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


27. Chan SL, Arifi AA, Chan AB, Chan AT, Ma BB: An unusual cause of superior vena cava obstruction. Thorax; 2006 Feb;61(2):182
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasms, Unknown Primary / complications. Neoplasms, Vascular Tissue / secondary. Superior Vena Cava Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 1981 Jul;56(7):407-13 [7253702.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17(4):384-8 [10773559.001]
  • (PMID = 16443714.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2104587
  •  go-up   go-down


28. Sancho-Chust JN, Ferreres J, Blanquer J: Mini-bronchoalveolar lavage (mini-BAL) in the cytological diagnosis of interstitial disorders with acute respiratory failure and mechanical ventilation. Arch Bronconeumol; 2010 Feb;46(2):101-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Bronchoalveolar Lavage Fluid / cytology. Escherichia coli Infections / diagnosis. Lung Diseases, Interstitial / diagnosis. Neoplasms, Unknown Primary. Pneumonia, Bacterial / diagnosis. Respiration, Artificial. Respiratory Insufficiency / etiology


29. Pentheroudakis G, Lazaridis G, Pavlidis N: Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat; 2010 Jan;119(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence.
  • Axillary lymph node metastases from adeno carcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) represent a rare clinical entity without consensus on its biology, management and outcome.
  • CUPAx affected women at a mean age of 52 years, 66% of whom post-menopausal harbouring low-volume (N1, 48%) or high-volume (52%) nodal disease from ductal adenocarcinoma (83%).
  • Among a total of 446 patients managed with mastectomy, a small breast primary was identified histologically in 321 (72% of cases).
  • CUPAx patients were managed with axillary lymph node dissection coupled to mastectomy (59%), primary breast irradiation (26%) or observation (15%).
  • [MeSH-major] Adenocarcinoma / pathology. Axilla / pathology. Carcinoma / pathology. Lymphatic Metastasis / diagnosis. Neoplasms, Unknown Primary / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19771506.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 46
  •  go-up   go-down


30. Ito S, Kodera Y, Mochizuki Y, Kojima T, Nakanishi H, Yamamura Y: Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR. World J Surg; 2010 Sep;34(9):2083-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with CEA mRNA exceeding a cutoff value have a significant risk for developing peritoneal carcinomatosis, but optimal treatment for this population remains unknown.
  • Overall survival, the primary endpoint of this phase II trial, was compared with the historical control, which is comprised of CEA mRNA (+) patients who were not given postoperative chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Feb;35(2):468-9; author reply 470-1 [20857104.001]
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):960-3 [17591103.001]
  • [Cites] Gastric Cancer. 2008;11(4):206-13 [19132482.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] Ann Surg Oncol. 2007 May;14 (5):1694-702 [17294072.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):687-92 [9310142.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):411-7 [11008202.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):653-9 [9815733.001]
  • [Cites] Langenbecks Arch Surg. 2005 Sep;390(5):430-41 [15991048.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Jpn J Clin Oncol. 2005 Nov;35(11):672-5 [16275676.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):986-92 [16205696.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S32-6 [10357556.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):581-9 [11520161.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):361-8 [16428473.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1158-63 [19328643.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2609-16 [18451223.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 20379713.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


31. Yamagami W, Banno K, Kawaguchi M, Yanokura M, Kuwabara Y, Hirao N, Susumu N, Tsukazaki K, Aoki D: Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report. Chemotherapy; 2007;53(2):137-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report.
  • The histopathological diagnosis was adenocarcinoma, mature cystic teratoma with malignant transformation, stage IV.
  • CONCLUSION: The CD-DST may be particularly useful for selecting preoperative chemotherapeutic drugs for patients with ovarian cancer in which the histological type of the primary tumor is unknown.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols. Collagen Type I. Drug Screening Assays, Antitumor. Ovarian Neoplasms / drug therapy. Teratoma / drug therapy

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17308380.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Collagen Type I; 0 / Gels; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


32. Dimitroulas T, Settas L: Paget's disease of the vulva in a patient with scleroderma and underlying adenocarcinoma: case report. Eur J Gynaecol Oncol; 2009;30(4):458-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paget's disease of the vulva in a patient with scleroderma and underlying adenocarcinoma: case report.
  • The patient underwent radical vulvectomy, but 18 months later died due to adenocarcinoma of unknown primary origin.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary. Neoplasms, Unknown Primary. Paget Disease, Extramammary / complications. Scleroderma, Systemic / complications. Vulvar Neoplasms / complications

  • Genetic Alliance. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761147.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Takeyama H, Takahashi H, Tabei I, Fukuchi O, Nogi H, Kinoshita S, Uchida K, Morikawa T: Malignant neoplasm in the axilla of a male: suspected primary carcinoma of an accessory mammary gland. Breast Cancer; 2010 Apr;17(2):151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant neoplasm in the axilla of a male: suspected primary carcinoma of an accessory mammary gland.
  • Incisional biopsy for suspected malignancy was performed, and histopathologic examination by hematoxylin-eosin (H&E) staining yielded a diagnosis of poorly differentiated adenocarcinoma metastatic from an unknown primary.
  • Detailed examination of the head and neck region, lung, and upper and lower gastrointestinal tract also revealed no evidence of a primary tumor.
  • On the basis of the histological features of H&E-stained specimens and immunohistochemistry of the resected tumor, this case was diagnosed as breast cancer of unknown origin in a male.
  • The tumor could have been an axillary lymph node metastasis from an occult breast carcinoma, or primary cancer arising in an accessory mammary gland.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms, Male / pathology. Neoplasms, Unknown Primary / pathology

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387775.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Park TW, Theuerkauf I, Morakkabati N: Orbital metastases of unknown origin: HPV typing identifies the primary tumor. Acta Obstet Gynecol Scand; 2005 Jul;84(7):702-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastases of unknown origin: HPV typing identifies the primary tumor.
  • [MeSH-major] Adenocarcinoma / virology. Orbital Neoplasms / virology. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / virology


35. Peng KL, Kao SC, Yang CF, Kau HC, Tsai CC, Hsu WM: Metastatic prostatic adenocarcinoma to the orbit diagnosed by prostate-specific antigen staining. Eye (Lond); 2008 Feb;22(2):320-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostatic adenocarcinoma to the orbit diagnosed by prostate-specific antigen staining.
  • [MeSH-major] Adenocarcinoma / secondary. Orbital Neoplasms / secondary. Prostate-Specific Antigen / analysis. Prostatic Neoplasms
  • [MeSH-minor] Aged. Humans. Male. Neoplasms, Unknown Primary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064052.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


36. Pentheroudakis G, Briasoulis E, Karavassilis V, Fountzilas G, Xeros N, Samelis G, Samantas E, Pavlidis N: Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective? Acta Oncol; 2005;44(2):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
  • Carcinoma of unknown primary (CUP) is characterized by dismal patient survival.
  • The outcome of patients with two favourable risk CUP subsets was studied.
  • The majority had poorly differentiated adenocarcinoma or undifferentiated carcinoma, treated with platinum-taxane based chemotherapy from 1996 till 2002.
  • Modern combination chemotherapy has satisfactory activity, with a minority of CUP patients enjoying long-term responses.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma / drug therapy. Neoplasms, Unknown Primary / drug therapy. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788295.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


37. Mhawech-Fauceglia P, Odunsi K, Dim D, Nowak N, Lele S, Cheney RT, Pejovic T: Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: mystery resolved? Int J Gynecol Pathol; 2008 Oct;27(4):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: mystery resolved?
  • Because of their rarity, the molecular characteristics of these tumors are still unknown.
  • To shed some light, we studied the genetic abnormalities of each of the 2 components, NEC and adenocarcinoma, in 4 cases arising in the ovary and the uterine corpus using array-comparative genomic hybridization.
  • However, the NEC components exhibited more genetic abnormalities in comparison with the adenocarcinoma, suggesting that when the NEC clones become more dedifferentiated, they acquire additional genetic abnormalities.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Neuroendocrine / genetics. Endometrial Neoplasms / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753966.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


38. Pugsley D, Bailly G, Gupta R, Wilke D, Wood L: Can Urol Assoc J; 2009 Jun;3(3):E4-E6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] A case of metastatic adenocarcinoma of the prostate arising in a meningioma.
  • We present the case of a 70-year-old man who had a prostate adenocarcinoma that metastatized to a previously unknown cranial meningioma.
  • Central nervous system (CNS) metastases are very uncommon in patients with prostate cancer, and metastases to pre-existing primary CNS tumours are even more uncommon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543455.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


39. Zielińska-Leś I, Kamiński J, Kozielski J: [Diagnostic difficulties in diffuse pulmonary infiltrations]. Wiad Lek; 2006;59(9-10):724-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological examination of supraclavicular lymph nodes and lung tissue obtained by transbronchial biopsy revealed metastatic adenocarcinoma.
  • Despite several examinations, including gastroscopy- the primary site of cancer was not established.
  • Post-mortem examination revealed diffuse gastric carcinoma as the primary neoplasm.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Unknown Primary / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338139.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


40. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alpha-methylacyl-coenzyme-A racemase (AMACR) is a sensitive marker of PC (except for a few uncommon variants: atrophic, foamy gland, and pseudohyperplastic variants), and its detection by immunohistochemical staining in atypical prostatic lesions can be very useful in confirming an impression of adenocarcinoma.
  • CDX2 and villin are useful markers to diagnostically separate colonic adenocarcinoma from PC.
  • PSA and PSAP immunohistochemical stains are valuable in confirming metastatic carcinoma as being of prostatic origin and should always be utilized in the diagnostic evaluation of metastatic adenocarcinoma of unknown primary origin in males.


41. Suzuki J, Kazama S, Kitayama J, Uozaki H, Miyata T, Nagawa H: Signet ring cell carcinoma of the appendix manifesting as colonic obstruction and ovarian tumors: report of a case. Surg Today; 2009;39(3):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of appendiceal adenocarcinoma manifesting as a colonic obstruction with a lower abdominal mass.
  • When a patient is found to have disseminated pelvic signet ring cell carcinoma of unknown origin, the appendix should be considered as a possible primary site.


42. Lee WB, Sy HM, Filip DJ, Grossniklaus HE: Metastatic esophageal adenocarcinoma presenting in the iris. Am J Ophthalmol; 2007 Sep;144(3):477-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic esophageal adenocarcinoma presenting in the iris.
  • PURPOSE: To report a case of metastatic esophageal adenocarcinoma presenting as an acute primary iris tumor of unknown origin.
  • RESULTS: Iris biopsy revealed the lesion represented metastasis, and a systemic evaluation later revealed the primary source as esophageal adenocarcinoma.
  • Tissue biopsy, tumor antigens, and a thorough systemic evaluation are crucial in identification of primary tumors in cases of unknown metastatic origin.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Iris Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765442.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Al-Brahim N, Ross C, Carter B, Chorneyko K: The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol; 2005 Apr;9(2):77-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center.
  • BACKGROUND: Metastasis of unknown origin (MUO) is a diagnostic challenge in clinical practice even with the state of current advanced diagnostic technology.
  • To evaluate the value of autopsy in determining the primary site of MUO, this study reviewed the Hamilton experience-over the last 20 years-with patients autopsied with clinical diagnosis of MUO.
  • Fifty-three cases of MUO were identified (MUO was defined as a patient with pathological and/or radiological diagnosis of a metastatic tumor for which the primary site of malignancy was unknown).
  • Pathological diagnoses at autopsy were adenocarcinoma (n = 37), small cell carcinoma (n = 6), anaplastic carcinoma (n = 3), and undifferentiated carcinoma (n = 3).
  • Primary tumors were identified in 27 patients (51%), most commonly in the lung (n = 8), large bowel (n = 6), and pancreas (n = 4).
  • Histochemical and immunohistochemical stains were helpful in reaching the diagnosis of a primary tumor in 4 of 27 cases.
  • (1) in this series, autopsy was helpful in establishing the diagnosis of a primary tumor in 51% of the cases, reaffirming the value of postmortem examination in these instances;.
  • (2) adenocarcinoma was the most frequent tumor presenting as MUO;.
  • (3) the lung and the large bowel were the most frequent sites for primary tumors; and (4) careful gross and histological examinations remain the most important tools in identifying the primary site.
  • [MeSH-major] Autopsy / standards. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806513.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Baehring JM, de Lotbiniere A, Bannykh S: Heteronymous inferior quadrantanopsia from a hypothalamic metastasis. J Neurooncol; 2005 Dec;75(3):345-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / secondary. Hemianopsia / etiology. Hypothalamic Neoplasms / complications. Hypothalamic Neoplasms / secondary
  • [MeSH-minor] Apoptosis. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Necrosis. Neoplasm Metastasis. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314960.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B, Gumus M, Uner A, Yamac D, Ucgul E, Buyukberber S: Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev; 2008 Oct-Dec;9(4):683-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.
  • PURPOSE: The aim of this study was to evaluate the role of whole body 18F-FDG PET/CT imaging in the detection of primary tumors in patients with a metastatic cancer from an unknown primary site.
  • According to the final pathologic diagnoses, rate of detection of the primary tumor site was determined.
  • RESULTS: A primary tumor site was shown by 18F-FDG PET/CT in 24 patients (24/43; 55.8%).
  • In a patient with an adenocarcinoma metastasis 18F-FDG PET/CT was falsely positive for an inflammatory lesion in the lung.
  • CONCLUSION: Whole body 18F-FDG PET/CT imaging has a high rate of detection of a primary tumor in patients with a carcinoma of unknown origin.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms, Unknown Primary / diagnostic imaging. Neoplasms, Unknown Primary / mortality. Positron-Emission Tomography / methods
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adult. Aged. Breast Neoplasms / diagnostic imaging. Breast Neoplasms / mortality. Breast Neoplasms / secondary. Cause of Death. Cohort Studies. Confidence Intervals. Female. Humans. Kaplan-Meier Estimate. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Statistics, Nonparametric. Stomach Neoplasms / diagnostic imaging. Stomach Neoplasms / mortality. Stomach Neoplasms / secondary. Survival Analysis. Tomography, X-Ray Computed / methods. Whole Body Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19256759.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Sugiyama Y, Morifuji M, Tatsumoto N, Sasaki M, Naito H, Kai Y: [A case of occult breast carcinoma with irradiation therapy and axillary lymph node dissection]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1287-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aspiration biopsy cytology of the left axillary node revealed adenocarcinoma.
  • Systemic examination failed to reveal primary lesion.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Lymph Node Excision. Neoplasms, Unknown Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969026.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. McKenney JK, Amin MB: The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol; 2005 Feb;22(1):69-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review, we discuss a series of distinct diagnostic scenarios, including high-grade undifferentiated carcinoma versus prostatic adenocarcinoma, enteric-type adenocarcinoma versus secondary colorectal adenocarcinoma, spindle cell proliferations, neoplasms with plasmacytoid morphology, endophytic tumors with a nested growth pattern, and flat urothelial lesions with atypia.
  • We also discuss markers supporting urothelial differentiation in the context of a metastatic carcinoma from an unknown primary.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Carcinoma / pathology. Child. Diagnosis, Differential. Humans. Male. Neoplasm Metastasis. Neoplasms, Unknown Primary / diagnosis. Precancerous Conditions. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512600.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 62
  •  go-up   go-down


48. Molina Garrido MJ, Guillén Ponce C, Maciá Escalante S, Pons Sanz V, Carrato Mena A: Cushing's paraneoplastic syndrome as first manifestation of an adenocarcinoma of unknown origin. Clin Transl Oncol; 2006 Aug;8(8):621-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's paraneoplastic syndrome as first manifestation of an adenocarcinoma of unknown origin.
  • We hereby present the case of a patient diagnosed with a metastatic carcinoma of unknown origin associated with two paraneoplastic syndromes: a Cushing's syndrome and a sensitive-motor axonal neuropathy, a very uncommon association.
  • [MeSH-major] ACTH Syndrome, Ectopic / etiology. Adenocarcinoma / diagnosis. Neoplasms, Unknown Primary / diagnosis. Paraneoplastic Polyneuropathy / etiology

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1990 Jul;50(1):52-7 [2164362.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):66-71 [1309310.001]
  • [Cites] Rev Mal Respir. 1999 Jun;16(3):395-7 [10472651.001]
  • [Cites] Eur J Endocrinol. 2001 Jan;144(1):81 [11174841.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602 [14671138.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):157-64 [7799015.001]
  • [Cites] An Sist Sanit Navar. 2005 May-Aug;28(2):213-26 [16155618.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Mar;32(3):275-81 [2160871.001]
  • [Cites] Intern Med. 2003 Sep;42(9):831-3 [14518671.001]
  • [Cites] N Engl J Med. 2000 Feb 10;342(6):414-20 [10666433.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Sep;23 (3):511-37 [7805651.001]
  • [Cites] Acta Radiol. 1999 Jan;40(1):100-3 [9973912.001]
  • (PMID = 16952854.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


49. Collins KA, Presnell SE: Asphyxia by tracheobronchial thrombus. Am J Forensic Med Pathol; 2005 Dec;26(4):327-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the deaths of 2 individuals, a 43-year-old female and a 78-year-old female, both with adenocarcinoma.
  • Experiencing a decline in mental status, the 78-year-old had metastatic adenocarcinoma of unknown primary.
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Aged. Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Female. Forensic Medicine. Humans. Neoplasms, Unknown Primary / complications. Respiratory Distress Syndrome, Adult / etiology


50. Chabottaux V, Sounni NE, Pennington CJ, English WR, van den Brûle F, Blacher S, Gilles C, Munaut C, Maquoi E, Lopez-Otin C, Murphy G, Edwards DR, Foidart JM, Noël A: Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res; 2006 May 15;66(10):5165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the contribution of MT1-MMP during different steps of cancer progression has been well documented, the significance of other MT-MMPs is rather unknown.
  • Stable transfection of MT4-MMP cDNA in human breast adenocarcinoma MDA-MB-231 cells does not affect in vitro cell proliferation or invasion but strongly promotes primary tumor growth and associated metastases in RAG-1 immunodeficient mice.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • ORBi (University of Liege). Free full Text at ORBi .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707440.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0100250
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases, Membrane-Associated
  •  go-up   go-down


51. Muggli B, Imhof A, Willimann P: [Pain therapy in general practice]. Praxis (Bern 1994); 2009 May 13;98(10):513-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Adenocarcinoma / physiopathology. Adenocarcinoma / secondary. Bone Neoplasms / physiopathology. Bone Neoplasms / secondary. Chronic Disease. Dose-Response Relationship, Drug. Drug Therapy, Combination. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / physiopathology. Pain / classification. Pain / etiology. Pain Measurement. Pain, Intractable / classification. Pain, Intractable / drug therapy. Pain, Intractable / etiology. Palliative Care. Spinal Neoplasms / physiopathology. Spinal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424945.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Analgesics; 0 / Analgesics, Opioid; 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


52. Hong KM, Yang SH, Chowdhuri SR, Player A, Hames M, Fukuoka J, Meerzaman D, Dracheva T, Sun Z, Yang P, Jen J: Inactivation of LLC1 gene in nonsmall cell lung cancer. Int J Cancer; 2007 Jun 1;120(11):2353-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serial analysis of gene expression studies led us to identify a previously unknown gene, c20orf85, that is present in the normal lung epithelium but absent or downregulated in most primary nonsmall cell lung cancers and lung cancer cell lines.
  • By in situ hybridization, we observed that LLC1 message is localized in normal lung bronchial epithelial cells but absent in 13 of 14 lung adenocarcinoma and 9 out of 10 lung squamous carcinoma samples.
  • Methylation at CpG sites of the LLC1 promoter was frequently observed in lung cancer cell lines and in a fraction of primary lung cancer tissues.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Nov 22;20(53):7699-709 [11753648.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1580-8 [12629521.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1596-601 [12670910.001]
  • [Cites] Breast Cancer Res Treat. 2003 Apr;78(3):337-45 [12755492.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):238-43 [12949800.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):900-3 [14624785.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] J Mol Diagn. 2004 May;6(2):90-5 [15096563.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4314-24 [15240517.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1196-209 [15492986.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Science. 1997 May 23;276(5316):1268-72 [9157888.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5690-4 [9865724.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):711-5 [10487828.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]
  • [Cites] Biotechniques. 2005 Mar;38(3):354, 356, 358 [15786801.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2106-10 [15788655.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3063-71 [15833835.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):299-306 [15892997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15203-8 [11752463.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3340-6 [12067970.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):282-7 [11391799.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1309-13 [11245426.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • (PMID = 17304513.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / Z01 CP010165-05; United States / PHS HHS / / R01 80127; United States / NCI NIH HHS / CP / Z01 CP010162-05; United States / PHS HHS / / R0184354; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CP / Z01 CP010164-05; United States / PHS HHS / / 0510370
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / C20orf85 protein, human; 0 / DNA Primers; 0 / Proteins
  • [Other-IDs] NLM/ NIHMS18699; NLM/ PMC1907378
  •  go-up   go-down


53. Angelucci A, Muzi P, Cristiano L, Millimaggi D, Cimini A, Dolo V, Miano R, Vicentini C, Cerù MP, Bologna M: Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. Prostate; 2008 May 1;68(6):588-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When prostatectomy fails to eradicate the primary tumor, PCa is generally refractory to all therapeutic approaches.
  • However molecular mechanisms underlying VPA action in PCa cells are largely unknown and further experimental validation to prove its potential application in clinic practice is needed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cell Transdifferentiation / drug effects. Enzyme Inhibitors / pharmacology. Neurosecretory Systems / drug effects. PPAR gamma / metabolism. Prostatic Neoplasms / drug therapy. Valproic Acid / pharmacology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288684.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-chloro-5-nitrobenzanilide; 0 / Anilides; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / PPAR gamma; 0 / Proto-Oncogene Proteins c-bcl-2; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


54. Arndt S, Bosserhoff AK: Reduced expression of TANGO in colon and hepatocellular carcinomas. Oncol Rep; 2007 Oct;18(4):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene codes for a 14-kDa protein of so far unknown function.
  • TANGO was down-regulated or lost in all hepatocellular and colon cell lines compared to primary human hepatocytes or normal colon epithelial cells, respectively, and in most of the tumor samples compared to non-tumorous tissue.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Line, Tumor. Down-Regulation. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786351.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ARNT protein, human; 0 / RNA, Messenger; 138391-32-9 / Aryl Hydrocarbon Receptor Nuclear Translocator
  •  go-up   go-down


55. Tominaga K, Iida T, Nakamura Y, Nagao J, Yokouchi Y, Maetani I: Small intestinal perforation of endoscopically unrecognized lesions during peroral single-balloon enteroscopy. Endoscopy; 2008 Sep;40 Suppl 2:E213-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endoscopy, Gastrointestinal / methods. Intestinal Perforation / diagnosis. Jejunal Neoplasms / diagnosis. Neoplasm Invasiveness / pathology. Neoplasms, Unknown Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819062.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK, Leung WK: Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer; 2007 Oct 8;97(7):895-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of secreted frizzled-related protein (SFRP) genes in gastric cancer remains largely unknown.
  • The expression and methylation status of four SFRP members (SFRP1, 2, 4, and 5) in primary gastric cancer samples was screened.
  • Promoter hypermethylation of SFRP2 was detected in 73.3% primary gastric cancer tissues, 37.5% of samples showing intestinal metaplasia and 20% adjacent normal gastric tissues.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Animals. Apoptosis. Azacitidine. Cell Line, Tumor. Cell Proliferation. DNA Primers / chemistry. Eye Proteins / genetics. Eye Proteins / metabolism. Flow Cytometry. Gene Silencing. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Mice. Mice, Nude. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2847-51 [11306456.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):45-51 [17208432.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):767-71 [11562753.001]
  • [Cites] Life Sci. 2001 Dec 14;70(4):483-9 [11798016.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):323-9 [11813881.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1761-6 [12060614.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):399-403 [12163364.001]
  • [Cites] Dev Dyn. 2002 Nov;225(3):260-70 [12412008.001]
  • [Cites] Exp Cell Res. 2002 Nov 1;280(2):280-7 [12413893.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):623-8 [12448005.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1560-5 [12771922.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] J Surg Oncol. 2004 Sep 15;87(4):182-6 [15334633.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26(3):215-20 [2357770.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13636-41 [9391078.001]
  • [Cites] J Pathol. 2005 Jan;205(2):130-44 [15641015.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2190-4 [15942635.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):584-91 [15825175.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7081-5 [16103055.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6323-7 [16007200.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7376-83 [16243810.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3216-21 [16707623.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1761-6 [16708382.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2294-301 [11413518.001]
  • (PMID = 17848950.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Eye Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / SFRP1 protein, human; 0 / SFRP2 protein, human; 0 / SFRP4 protein, human; 0 / SFRP5 protein, human; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2360406
  •  go-up   go-down


57. Ettl T, Kleinheinz J, Mehrotra R, Schwarz S, Reichert TE, Driemel O: The buccal minor salivary glands as starting point for a metastasizing adenocarcinoma--report of a case. Head Face Med; 2008;4:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The buccal minor salivary glands as starting point for a metastasizing adenocarcinoma--report of a case.
  • BACKGROUND: With the 2005 WHO classification of salivary gland tumours and its increasingly recognized diagnostic entities, the frequency of adenocarcinoma (NOS) has decreased significantly.
  • CASE PRESENTATION: This paper describes a fast growing adenocarcinoma (NOS), originating from the minor salivary glands of the left buccal mucosa with a rapid onset of multiple local and distant metastases, especially in the lung.
  • A lung primary was unlikely as the tumour was characterized by positivity for cytokeratin 20 and negativity for the thyroid transcription factor-1 protein (TTF-1) in immunohistochemistry.
  • CONCLUSION: A rare case of an adenocarcinoma (NOS) of the minor salivary glands with a rapid development and an unfavourable clinical course is reported.
  • It shows that additional immunohistochemical analysis can decisively contribute to determine the site of the primary tumour in cases with unknown primary.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Neoplasm Metastasis. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • [Cites] Cancer. 2001 Oct 25;93(5):330-6 [11668468.001]
  • [Cites] Lung Cancer. 2004 May;44(2):149-57 [15084379.001]
  • [Cites] Am J Surg. 1982 Oct;144(4):423-31 [7125074.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Laryngoscope. 1988 Jul;98(7):784-8 [3386387.001]
  • [Cites] Histopathology. 2007 Jul;51(1):26-32 [17593078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Dec;128(12):1385-94 [15578883.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):805-10 [15944978.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103(3):308-13 [17197205.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jul;104(1):94-100 [17577550.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Jan;101(1):102-4 [1728879.001]
  • (PMID = 18667060.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  • [Other-IDs] NLM/ PMC2515301
  •  go-up   go-down


58. Yu KJ, Lee HE, Ho HC, Lee JC, Chang JW, Hong HS, Yang CH: Carcinoma erysipelatoides from squamous cell carcinoma of unknown origin. Int J Clin Pract; 2005 Sep;59(9):1104-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma erysipelatoides from squamous cell carcinoma of unknown origin.
  • It is frequently observed in patients with breast carcinoma as well as adenocarcinoma of pancreas, rectum, lung, ovary and parotid gland.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Neoplasms, Unknown Primary / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115190.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


59. Rodríguez JM, Sanz Peláez O, Santana L, Rey A, Suárez Ortega S, Betancor León P: [The Sister Joseph's nodule-like manifestation of carcinoma of unknown origin: presentation of one case]. An Med Interna; 2005 Jun;22(6):285-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The Sister Joseph's nodule-like manifestation of carcinoma of unknown origin: presentation of one case].
  • We presents a 71-year-old male, with the Sister Joseph's nodule, detected in the context of unknown origin carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Neoplasms, Unknown Primary / pathology. Skin Neoplasms / secondary. Umbilicus

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16011409.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Baloch ZW, LiVolsi VA: Microcarcinoma of the thyroid. Adv Anat Pathol; 2006 Mar;13(2):69-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the less common scenario, the microcarcinoma is the primary lesion to a lymph node metastasis presenting clinically as a neck mass; in this situation, the tumor should be treated as a clinical cancer.
  • However, when found as sporadic tumors, their implications are still unknown.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670460.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 84
  •  go-up   go-down


61. Merchant NB, Rymer J, Koehler EA, Ayers GD, Castellanos J, Kooby DA, Weber SH, Cho CS, Schmidt CM, Nakeeb A, Matos JM, Scoggins CR, Martin RC, Kim HJ, Ahmad SA, Chu CK, McClaine R, Bednarski BK, Staley CA, Sharp K, Parikh AA: Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg; 2009 May;208(5):829-38; discussion 838-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits?
  • The primary aim of this study was to determine if CRT improved survival in patients with resected pancreatic cancer in a large, multiinstitutional cohort of patients.
  • STUDY DESIGN: Patients undergoing resection for pancreatic adenocarcinoma from seven academic medical institutions were included.
  • Exclusion criteria included patients with T4 or M1 disease, R2 resection margin, preoperative therapy, chemotherapy alone, or if adjuvant therapy status was unknown.
  • Primary analysis was performed between patients that had surgery alone (n=374) and those receiving adjuvant CRT (n=299).
  • CONCLUSIONS: This large multiinstitutional study emphasizes the importance of analyzing subsets of patients with pancreas adenocarcinoma who have LN metastasis.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):74-85 [12496533.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):52-60 [17592291.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2081-8 [18461404.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4532-7 [16002844.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2773-86 [18612703.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • (PMID = 19476845.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA098240
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS627213; NLM/ PMC4167601
  •  go-up   go-down


62. Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D: Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol; 2008 Sep 20;26(27):4435-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
  • PURPOSE: Patients with adenocarcinoma of unknown primary origin (ACUP) constitute approximately 4% of all malignancies.
  • For effective treatment of these patients, it is considered optimal to identify the primary tumor origins.
  • PATIENTS AND METHODS: Formalin-fixed, paraffin-embedded (FFPE) samples were obtained from 84 patients with a known primary adenocarcinoma and from 38 patients with ACUP.
  • RESULTS: The gene expression-based assay classified the primary site correctly in 70 (83%) of 84 patient cases of primary and metastatic tumors of known origin, with good sensitivity for the majority of the tumor classes and relatively poor sensitivity for primary lung adenocarcinoma.
  • CONCLUSION: The gene expression platform can classify correctly from FFPE samples the majority of tumors classes both in patients with known primary and in patients with ACUP.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Gene Expression Profiling. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Feb 1;27(4):649-50; author reply 650-2 [19114684.001]
  • [CommentIn] J Clin Oncol. 2008 Sep 20;26(27):4373-5 [18802148.001]
  • (PMID = 18802156.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Rifatbegović Z, Mesić D, Ljuca F, Zildzić M, Morankić M: [Incidence and surgical treatment of cancer in gallbladder]. Med Arh; 2007;61(1):30-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gallbladder cancer is the most common primary cancer of the hepatobiliary system, and ranks fifth of the cancers of the gastrointestinal system.
  • The etiology of this disease is unknown.
  • In 38 (88,4 %) patients it was adenocarcinoma of the gallbladder.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582972.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


64. Loo SW, Ford H, Lu SJ: Blindness, confusion and seizures in a cancer patient. Neth J Med; 2010 Feb;68(2):95-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / complications. Blindness / etiology. Confusion / etiology. Neoplasms, Unknown Primary / pathology. Posterior Leukoencephalopathy Syndrome / diagnosis. Seizures / etiology

  • Genetic Alliance. consumer health - Seizures.
  • Genetic Alliance. consumer health - Blindness.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20167964.001).
  • [ISSN] 1872-9061
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


65. Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK: The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol; 2010 Dec 25;118(6):441-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas.
  • Napsin-A, which is expressed in lung tissue, is a relatively new marker for lung adenocarcinoma.
  • In this study, the authors examined the utility of napsin-A compared with TTF-1 in cytologic specimens of primary and metastatic, poorly differentiated lung adenocarcinomas.
  • METHODS: The archives of the Department of Pathology at The Johns Hopkins Hospital were searched for cytologic cases of poorly differentiated lung adenocarcinoma that were histologically confirmed.
  • Tissue microarrays of lung adenocarcinoma also were examined.
  • CONCLUSIONS: Although TTF-1 had a higher sensitivity, napsin-A was useful as a surrogate marker when encountering a poorly differentiated lung adenocarcinoma or an unknown primary tumor, particularly in cytologic specimens and difficult cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Aspartic Acid Endopeptidases / analysis. Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Nuclear Proteins / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20830690.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


66. Chiosea S, Shuai Y, Cieply K, Nikiforova MN, Dacic S: EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Hum Pathol; 2010 Aug;41(8):1053-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
  • The incidence of KRAS and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations in EGFR-amplified or EGFR FISH-positive lung adenocarcinomas remains unknown.
  • Of 386 primary lung adenocarcinomas, 77 (20%) were EGFR FISH positive by University of Colorado criteria.
  • The incidence of KRAS mutations in EGFR FISH-positive lung adenocarcinomas was 23% and was not significantly different from the incidence of KRAS mutations in EGFR FISH-negative subsets of adenocarcinoma (32%).
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics


67. Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, Macmillan D, Blamey RW, Ellis IO: Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol; 2010 Jan 1;28(1):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE Although tubular carcinoma (TC) is known to have a favorable prognosis, it is still unknown whether this subtype represents a distinct type of breast carcinoma or whether it behaves like other low-grade luminal A-type breast carcinomas.
  • Patients with TC may be at risk of developing second primary carcinomas in the contralateral breast, which may be of higher grade and poorer potential prognostic outcome.
  • [MeSH-major] Adenocarcinoma / mortality. Breast Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917872.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Lima WR, Parreira KS, Devuyst O, Caplanusi A, N'kuli F, Marien B, Van Der Smissen P, Alves PM, Verroust P, Christensen EI, Terzi F, Matter K, Balda MS, Pierreux CE, Courtoy PJ: ZONAB promotes proliferation and represses differentiation of proximal tubule epithelial cells. J Am Soc Nephrol; 2010 Mar;21(3):478-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor zonula occludens 1 (ZO-1)-associated nucleic acid binding protein (ZONAB) can shuttle between tight junctions and nuclei, promoting cell proliferation and expression of cyclin D1 and proliferating cell nuclear antigen (PCNA), but whether it also represses epithelial differentiation is unknown.
  • Here, during mouse kidney ontogeny and polarization of proximal tubular cells (OK cells), ZONAB and PCNA levels decreased in parallel and inversely correlated with increasing apical differentiation, reflected by expression of megalin/cubilin, maturation of the brush border, and extension of the primary cilium.
  • In confluent OK cells, ZONAB overexpression increased proliferation and PCNA while repressing megalin/cubilin expression and impairing differentiation of the brush border and primary cilium.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / physiopathology. Adult. Animals. Cell Differentiation / physiology. Cell Division / physiology. Cell Line, Tumor. Cell Polarity / physiology. Down-Regulation / physiology. Epithelial Cells / cytology. Epithelial Cells / physiology. Gene Expression Regulation, Developmental. Humans. Kidney Neoplasms / pathology. Kidney Neoplasms / physiopathology. Low Density Lipoprotein Receptor-Related Protein-2 / genetics. Mice. Mice, Inbred C57BL. Opossums. Promoter Regions, Genetic / physiology. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Transcription Factors. Transfection

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51298-304 [15381696.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1507-15 [1531833.001]
  • [Cites] Lab Invest. 2005 Apr;85(4):452-63 [15723088.001]
  • [Cites] Cell. 2005 Sep 23;122(6):947-56 [16153702.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7354-61 [16243807.001]
  • [Cites] Nat Genet. 2006 Jan;38(1):21-3 [16341222.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):532-41 [16472605.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2387-98 [16508013.001]
  • [Cites] Traffic. 2006 May;7(5):589-603 [16643281.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6903-7 [16849532.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:17 [16722557.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:207-35 [16771626.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:125-48 [16722803.001]
  • [Cites] J Cell Sci. 2006 Dec 15;119(Pt 24):5098-105 [17158914.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5407-12 [17369355.001]
  • [Cites] J Cell Sci. 2007 May 1;120(Pt 9):1505-11 [17452622.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1255-7 [17604715.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1351-63 [17604723.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:345-73 [17506691.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):70-6 [18084282.001]
  • [Cites] Cell Stem Cell. 2008 Mar 6;2(3):284-91 [18371453.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):2128-39 [18307996.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Jun;294(6):F1273-8 [18287399.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Aug;295(2):C529-37 [18495814.001]
  • [Cites] Cancer Lett. 2009 Jan 8;273(1):35-43 [18809243.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(3):1089-101 [19073886.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1788(4):761-7 [19121284.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):156-64, 164.e1-3 [19328795.001]
  • [Cites] EMBO Rep. 2009 Oct;10(10):1125-31 [19730435.001]
  • [Cites] Science. 2006 Aug 4;313(5787):629-33 [16888132.001]
  • [Cites] EMBO J. 2005 Jan 12;24(1):54-62 [15592429.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):969-76 [15698435.001]
  • [Cites] EMBO J. 2000 May 2;19(9):2024-33 [10790369.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):369-73 [11099045.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 9;281(4):936-44 [11237751.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Apr;3(4):256-66 [11994745.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):423-32 [12566432.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):766-74 [12700771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8472-7 [12815097.001]
  • [Cites] Gene Expr Patterns. 2003 Oct;3(5):639-44 [12971999.001]
  • [Cites] BMC Cancer. 2003 Nov 27;3:31 [14641932.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 10;322(1):297-302 [15313206.001]
  • [Cites] Cell. 1989 Nov 3;59(3):461-75 [2680107.001]
  • [CommentIn] J Am Soc Nephrol. 2010 Mar;21(3):388-90 [20133486.001]
  • (PMID = 20133480.001).
  • [ISSN] 1533-3450
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0700743; United Kingdom / Medical Research Council / / G0900098
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CSDA protein, human; 0 / Csda protein, mouse; 0 / DNA-Binding Proteins; 0 / Heat-Shock Proteins; 0 / Low Density Lipoprotein Receptor-Related Protein-2; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / intrinsic factor-cobalamin receptor
  • [Other-IDs] NLM/ PMC2831853
  •  go-up   go-down


69. Zhang PJ, Gao HG, Pasha TL, Litzky L, Livolsi VA: TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol; 2009 Jan;28(1):10-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TTF-1 has been used as a reliable lineage marker for lung adenocarcinoma and thyroid carcinoma in surgical pathology.
  • We evaluated TTF-1 expression with 3 primary different antibodies (8G7G3/1, SPT24, and BGX-397A) and 2 secondary automated detection systems (Envision+/Dako autostainer versus Refine/Bond Max) in 104 ovarian and endometrial tumors on routine surgical specimens and 108 ovarian tumors on tissue microarray (TMA) specimens.
  • SPT24 and Refine/Bond Max autostainer was the most sensitive system among the primary antibodies and secondary detection/autostainers tested.
  • However, the role of TTF-1 in female genital tract and its tumors is unknown.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047914.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


70. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Matrix metalloproteinases in carcinoma of unknown primary. Cancer; 2005 Nov 15;104(10):2282-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinases in carcinoma of unknown primary.
  • BACKGROUND: The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP).
  • METHODS: Paraffin-embedded tumor material from 75 patients diagnosed with CUP was used.
  • Tumor histologies were adenocarcinoma (77%), undifferentiated carcinoma (19%), and squamous cell carcinoma (4%) and patients were categorized into favorable (62%) and unfavorable (38%) subsets.
  • CONCLUSIONS: MMP-2, MMP-9, and TIMP-1 are widely expressed in CUP, suggesting an essential role of proteolysis in these tumors.
  • TIMP-1 may be considered a possible marker of poor prognosis in CUP patients.
  • [MeSH-major] Carcinoma / enzymology. Carcinoma / secondary. Matrix Metalloproteinases / metabolism. Neoplasms, Unknown Primary / enzymology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16220559.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


71. McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar JN, Boeve BF, Mullan B, Mokri B, Britton JW, Drubach DA, Pittock SJ: Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol; 2010 Mar;67(3):322-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancers detected (limited stage in 9 of 10 patients and extratruncal in 4) were as follows: 2 thyroid papillary cell carcinomas, 3 solitary lymph nodes with unknown primary (2 adenocarcinomas and 1 small cell carcinoma), 1 tonsil squamous cell carcinoma, 3 lung carcinomas (1 adenocarcinoma, 1 small cell, and 1 squamous cell), and 1 colon adenocarcinoma.

  • Genetic Alliance. consumer health - Paraneoplastic Neurologic Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065123.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol; 2006 Jan 1;24(1):25-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six objective responses were observed in three renal cell carcinomas, one neuroendocrine tumor, one stromal tumor, and one unknown primary adenocarcinoma patient.


73. Wu JM, Ali SZ: Significance of "signet-ring cells" seen in exfoliative and aspiration cytopathology. Diagn Cytopathol; 2010 Jun;38(6):413-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the malignant lesions, 47 (72%) were metastases, 14 (22%) were primary cancers and 4 (6%) were local cancer recurrences.
  • Adenocarcinoma was the most prevalent malignant diagnosis (53, 82%).
  • Most cancers with SRCs are metastatic in origin (72%) with a significant proportion from unknown primaries (51%).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19937761.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Pneumaticos SG, Chatziioannou SN, Savvidou C, Pilichou A, Rontogianni D, Korres DS: Routine needle biopsy during vertebral augmentation procedures. Is it necessary? Eur Spine J; 2010 Nov;19(11):1894-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the last patient, namely the one with pancreatic cancer, the workup did not identify the origin of the primary tumor, although the patient was considered to have a compression fracture secondary to metastatic disease of unknown origin, the vertebral biopsy suggested the presence of adenocarcinoma which eventually was proven to be pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone. 1992;13 Suppl 2:S27-31 [1627411.001]
  • [Cites] Am Rev Respir Dis. 1990 Jan;141(1):68-71 [2297189.001]
  • [Cites] Bone. 1994 Jan-Feb;15(1):27-30 [8024847.001]
  • [Cites] Bone. 1995 Nov;17(5 Suppl):505S-511S [8573428.001]
  • [Cites] Bone. 1996 Mar;18(3 Suppl):185S-189S [8777086.001]
  • [Cites] Radiol Clin North Am. 1998 May;36(3):533-46 [9597071.001]
  • [Cites] Osteoporos Int. 1998;8(3):261-7 [9797911.001]
  • [Cites] Arch Intern Med. 1999 Jun 14;159(11):1215-20 [10371229.001]
  • [Cites] Spine (Phila Pa 1976). 2005 Apr 1;30(7):781-6 [15803081.001]
  • [Cites] J Bone Joint Surg Am. 2006 Dec;88(12):2721-4 [17142423.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Apr 15;25(8):923-8 [10767803.001]
  • [Cites] Spine (Phila Pa 1976). 2000 May 1;25(9):1051-2 [10788846.001]
  • [Cites] Eur Spine J. 2000 Oct;9(5):445-50 [11057541.001]
  • [Cites] Spine (Phila Pa 1976). 2001 Jul 15;26(14):1511-5 [11462078.001]
  • [Cites] Clin Imaging. 2002 Jan-Feb;26(1):1-5 [11814744.001]
  • [Cites] J Vasc Interv Radiol. 2002 Feb;13(2 Pt 1):137-8 [11830618.001]
  • [Cites] Neuroradiology. 2002 Nov;44(11):950-4 [12428134.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1 Suppl):36-42 [12546386.001]
  • [Cites] Radiology. 2003 Jun;227(3):662-8 [12702821.001]
  • [Cites] Orthopade. 2004 Jan;33(1):22-30 [14747907.001]
  • [Cites] Eur Spine J. 2004 May;13(3):184-92 [14986073.001]
  • [Cites] Spine (Phila Pa 1976). 2004 Oct 1;29(19):2120-5 [15454702.001]
  • [Cites] Neurochirurgie. 1987;33(2):166-8 [3600949.001]
  • [Cites] Arthritis Rheum. 1993 Jun;36(6):750-6 [8507215.001]
  • (PMID = 20372942.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2989251
  •  go-up   go-down


75. Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M: Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol; 2005 Dec;29(12):1224-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases from carcinomas of unknown primary site.
  • AIM: Hepatic metastases are often present at diagnosis of carcinoma of unknown primary site (CUP).
  • METHODS: One hundred and eighteen patients were treated at the Cancer Center of Montpellier from 1993 to 2002 for CUP initially metastatic to the liver.
  • RESULTS: The most frequent histological types observed were adenocarcinoma, undifferentiated, neuroendocrine and squamous-cell carcinomas.
  • CONCLUSIONS: According to this study, pretreatment evaluations, which were very extensive in some patients, were insufficient to identify the primary site of liver metastases.
  • [MeSH-major] Liver Neoplasms / mortality. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518276.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


76. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell; 2009 Jul 10;138(1):51-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
  • Metastasis from lung adenocarcinoma can occur swiftly to multiple organs within months of diagnosis.
  • The mechanisms that confer this rapid metastatic capacity to lung tumors are unknown.
  • Activation of the canonical WNT/TCF pathway is identified here as a determinant of metastasis to brain and bone during lung adenocarcinoma progression.
  • Gene expression signatures denoting WNT/TCF activation are associated with relapse to multiple organs in primary lung adenocarcinoma.
  • Metastatic subpopulations isolated from independent lymph node-derived lung adenocarcinoma cell lines harbor a hyperactive WNT/TCF pathway.
  • Thus, a distinct WNT/TCF signaling program through LEF1 and HOXB9 enhances the competence of lung adenocarcinoma cells to colonize the bones and the brain.


77. Morishita Y, Kasakura Y, Kobayashi M, Mochizuki F, Yamagata M, Fujii M, Takayama T: Complete cure of metastatic gastric cancer treated with combination chemotherapy using S-1. Hepatogastroenterology; 2005 Nov-Dec;52(66):1933-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary lesion became scar ulceration and adenocarcinoma tissue was recognized by biopsy pathologically.
  • Although the outcome is still unknown, the effect of S-1 for adjuvant chemotherapy may be also promising.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334810.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEP protocol
  •  go-up   go-down


78. Speel EJ, van de Wouw AJ, Claessen SM, Haesevoets A, Hopman AH, van der Wurff AA, Osieka R, Buettner R, Hillen HF, Ramaekers FC: Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma. Int J Cancer; 2008 Sep 15;123(6):1292-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.
  • Unknown primary adenocarcinoma (UPA) comprises a group of heterogeneous cancers of great clinical and biological interest.
  • UPA presents as metastatic disease without a detectable primary site after medical workup.
  • A molecular resemblance would argue for an early clonal outgrowth of tumor cells from the primary lesion, a mutual feature observed within this group of neoplasms.
  • The molecular data indicated that the multiple lesions in the 14 UPA patients, including the primary tumors, are clonally related.
  • In agreement with the theory of tumor progression, some metastatic lesions showed additional genetic alterations besides the characteristics that were shared with the primary tumor.
  • Our data provide molecular evidence for a clonal relationship between multiple metastases and the primary tumor within individual UPA patients, independent of the anatomical origin of the cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Neoplasm Metastasis / genetics. Neoplasms, Unknown Primary / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18561313.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44v6 antigen
  •  go-up   go-down


79. Pivot X, Koralewski P, Hidalgo JL, Chan A, Gonçalves A, Schwartsmann G, Assadourian S, Lotz JP: A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol; 2008 Sep;19(9):1547-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary end point was the objective response rate (ORR) assessed according to response evaluation criteria in solid tumours (RECIST) guidelines.
  • Two deaths were reported, one related to study drug and one to unknown cause.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436520.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bridged Compounds; 0 / Taxoids; 0 / XRP6258; 1605-68-1 / taxane
  •  go-up   go-down


80. Lequin D, Fizazi K, Toujani S, Souquère S, Mathieu MC, Hainaut P, Bernheim A, Praz F, Busson P: Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary). BMC Cancer; 2007;7:225
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary).
  • BACKGROUND: Carcinomas of unknown primary site (CUP) are epithelial malignancies revealed by metastatic lesions in the absence of any detectable primary tumor.
  • METHODS: We attempted xenografts of CUP clinical specimens in immunodeficient mice and subsequent in vitro culture of transplanted malignant cells.
  • Distinct rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon 181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens.
  • CONCLUSION: Our data suggest that xenografted tumors can be obtained from a substantial fraction of CUP clinical specimens.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic. Neoplasm Transplantation / pathology. Neoplasms, Unknown Primary / genetics. Neoplasms, Unknown Primary / pathology. Transplantation, Heterologous / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):857-61 [17876336.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2026-36 [17698346.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):186-94 [11774263.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):409-13 [11818207.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):23-31 [12659667.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3479-82 [12972523.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):297-301 [15015611.001]
  • [Cites] Anticancer Res. 1993 Sep-Oct;13(5A):1619-23 [8239543.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4952-60 [8756654.001]
  • [Cites] Diagn Mol Pathol. 1998 Oct;7(5):260-6 [9990484.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4765-9 [10519380.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):119-29 [15798092.001]
  • [Cites] Clin Chem. 2005 Jul;51(7):1284-7 [15976115.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):139-48 [17210693.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] Oncologist. 2007 Apr;12(4):418-25 [17470684.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):391-406 [17368733.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • (PMID = 18088404.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2241840
  •  go-up   go-down


81. Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Tsuchiya T, Hisada T, Mori M: Forearm muscle metastasis as an initial clinical manifestation of lung cancer. South Med J; 2009 Jan;102(1):79-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skeletal muscle metastasis from lung cancer is rare, and the optimal treatment strategy is unknown.
  • A biopsy of the swollen muscle disclosed the presence of pulmonary adenocarcinoma.
  • The patient was treated with systemic chemotherapy and radiotherapy; radiographic examination revealed a marked reduction of the tumor in the primary site and muscle metastasis.
  • Skeletal muscle metastasis as a mode of presentation of primary lung cancer is an unusual phenomenon.
  • [MeSH-major] Adenocarcinoma / secondary. Forearm. Lung Neoplasms / pathology. Muscle Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077783.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Calabrese L, Jereczek-Fossa BA, Jassem J, Rocca A, Bruschini R, Orecchia R, Chiesa F: Diagnosis and management of neck metastases from an unknown primary. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):2-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of neck metastases from an unknown primary.
  • Neck lymph node metastases from occult primary constitute about 5%-10% of all patients with carcinoma of unknown primary site.
  • Diagnostic procedures include a careful clinical evaluation and a fiberoptic endoscopic examination of the head and neck mucosa, biopsies from all suspicious sites or blindly from the sites of possible origin of the primary, computerized tomography scan, and magnetic resonance.
  • In these cases, a systematic tonsillectomy in the absence of suspicious lesions is discussed since up to 25% of primary tumours can be detected in this site.
  • Thoracic, and abdominal primaries (especially from lung, oesophagus, stomach, ovary or pancreas) should be sought in the case of adenocarcinoma and involvement of the lower neck.
  • Positron emission tomography with fluoro-2-deoxy-D-glucose allows detection of primary tumour in about 25% of cases, but this procedure is still considered investigational.
  • A potential benefit from extensive radiotherapy should be weighed against its acute and late morbidity and difficulties in re-irradiation in the case of subsequent primary emergence.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary

  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):411-6 [12634970.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Sep;260(8):436-43 [12684829.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Oct;260(9):490-3 [12739031.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):153-64 [15023433.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Cancer Treat Rev. 2004 Jun;30(4):369-84 [15145511.001]
  • [Cites] Cancer. 1973 Apr;31(4):854-9 [4706050.001]
  • [Cites] Radiology. 1974 Mar;110(3):659-63 [4130047.001]
  • [Cites] Am J Surg. 1977 Oct;134(4):517-22 [911038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):73-6 [422418.001]
  • [Cites] Clin Radiol. 1980 May;31(3):355-8 [7428277.001]
  • [Cites] Radiology. 1984 Sep;152(3):749-53 [6463256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 May;12(5):733-40 [3710857.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Jun;94(5):605-10 [3088524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2101-10 [3793546.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Mar;124(3):331-3 [11241001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):55-63 [11316546.001]
  • [Cites] Acta Oncol. 2001;40(1):24-8 [11321655.001]
  • [Cites] Radiother Oncol. 2001 Jun;59(3):319-21 [11369074.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):727-33 [11395241.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):535-40 [11398889.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):214-6 [11408815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):4-9 [11516844.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1057-8 [11583184.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1605-9 [11822762.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):510-5 [2736495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):289-94 [2303361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):919-28 [2211260.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):443-6 [2221252.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Dec;116(12):1388-93 [2248737.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):463-9 [2258284.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):177-83 [2037468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):743-9 [1618667.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):884-90 [1495353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):619-22 [8454479.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1756-61 [8348505.001]
  • [Cites] Head Neck. 1994 Jan-Feb;16(1):58-63 [8125789.001]
  • [Cites] Cancer Treat Rev. 1994 Apr;20(2):119-47 [8156538.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):395-9 [7977958.001]
  • [Cites] Laryngoscope. 1995 May;105(5 Pt 1):548-50 [7760677.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):190-8 [7782203.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):222-8 [7546677.001]
  • [Cites] Radiother Oncol. 1995 Jun;35(3):206-11 [7480823.001]
  • [Cites] Radiology. 1996 Jun;199(3):761-6 [8638002.001]
  • [Cites] J Laryngol Otol. 1996 Apr;110(4):353-6 [8733457.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1996;113(4):212-8 [9033687.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):797-802 [9128954.001]
  • [Cites] Strahlenther Onkol. 1997 Jul;173(7):362-8 [9265258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):291-6 [9308930.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(5):322-9 [9368728.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):121-5 [9537194.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1998 Apr;23(2):158-63 [9597287.001]
  • [Cites] Laryngoscope. 1998 Oct;108(10):1578-83 [9778305.001]
  • [Cites] Head Neck. 1998 Dec;20(8):674-81 [9790287.001]
  • [Cites] Head Neck. 1998 Dec;20(8):739-44 [9790297.001]
  • [Cites] Laryngoscope. 1998 Nov;108(11 Pt 1):1605-10 [9818813.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):33-40 [9886695.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):599-604 [10203278.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):114-8 [10391570.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Jul;108(7 Pt 1):700-4 [10435932.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):214-8 [10439166.001]
  • [Cites] Oncologist. 2005 Mar;10(3):215-24 [15793225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jan;122(1):52-5 [10629482.001]
  • [Cites] Int J Hyperthermia. 2000 Jan-Feb;16(1):85-93 [10669319.001]
  • [Cites] Aust N Z J Surg. 2000 Apr;70(4):263-8 [10779057.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):121-9 [10799723.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 2000 May;103(5):524-8 [10853340.001]
  • [Cites] Head Neck. 2000 Jul;22(4):336-40 [10862015.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Jul 8;144(28):1355-60 [10923158.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Sep;123(3):294-301 [10964310.001]
  • [Cites] Otolaryngol Pol. 2000;54 Suppl 31:258-61 [10974901.001]
  • [Cites] Head Neck. 2002 Mar;24(3):236-46 [11891955.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2002;56(1):77-82 [11894635.001]
  • [Cites] Head Neck. 2002 Apr;24(4):361-9 [11933178.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):323-9 [11981279.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Jul;259(6):325-33 [12115082.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1024-30 [12173016.001]
  • [Cites] Acta Otolaryngol. 2002 Jul;122(5):569-74 [12206272.001]
  • [Cites] Cancer Control. 2002 Sep-Oct;9(5):387-99 [12410178.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):2009-14 [12439171.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Oral Maxillofac Surg. 2002 Dec;40(6):484-7 [12464205.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Head Neck. 2003 Feb;25(2):138-45 [12509797.001]
  • [Cites] Acta Otorrinolaringol Esp. 2002 Oct;53(8):601-6 [12530200.001]
  • (PMID = 16080309.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 102
  • [Other-IDs] NLM/ PMC2639847
  •  go-up   go-down


83. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.


84. Yonemori K, Ando M, Shibata T, Katsumata N, Matsumoto K, Yamanaka Y, Kouno T, Shimizu C, Fujiwara Y: Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Cancer Res Clin Oncol; 2006 Oct;132(10):635-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.
  • OBJECTIVES: To evaluate the usefulness of tumor-marker measurements and to identify prognostic factors in patients with cancer of unknown primary (CUP), receiving platinum-based combination chemotherapy and to verify the adjustment of previously reported prognostic models in this population.
  • METHODS: We conducted univariate and multivariate analyses in consecutive patients with CUP receiving platinum-based combination chemotherapy.
  • The ST-439 level was significantly higher in patients with histologically confirmed adenocarcinoma than in patients with poorly differentiated adenocarcinoma or poorly differentiated carcinoma.
  • CONCLUSION: Tumor-marker measurements are not helpful in the management of patients with CUP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Neoplasms, Unknown Primary / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1994;22(3):162-7 [7505876.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Cancer. 1981 Sep 1;48(5):1242-4 [6268281.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1720-5 [7541451.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2357-9 [9038622.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):297-301 [15015611.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3):286-93 [12063682.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2655-60 [11135228.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • [Cites] Cancer. 2004 May 1;100(9):1776-85 [15112256.001]
  • (PMID = 16791594.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


85. Hu M, Li MH, Kong L, Liu NB, Yang GR, Yu JM: [(18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):699-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [(18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin].
  • OBJECTIVE: To evaluate the value of (18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin.
  • METHODS: Sixty-seven patients with metastatic cancers of unknown primary origin after extensive conventional diagnostic work-up were enrolled into this study. (18)F-FDG PET-CT scans were performed at approximately 60 minutes after the intravenous injection of 7.4 MBq (18)F-FDG/kg, then delayed imaging scans was done at approximately 180 minutes for detecting the primary focus.
  • The correlation between (18)F-FDG PET-CT results and histopathological and clinical findings were analyzed, and the SUV of detected primary focus and that of metastatic cancers were compared.
  • RESULTS: Of the 67 patients, the primary tumors were identified in 39 (53.7%) by (18)F-FDG PET-CT, and 36 of them were confirmed by pathology or follow-up.
  • The SUV of metastatic tumors was significantly lower than that of primary tumors (t = 3.470,P = 0.001) and closely correlated with that of the primary tumors (r = 0.738, P = 0.000).
  • CONCLUSION: (18)F-FDG PET-CT is not only valuable in identifying the unknown primary tumor in patients with metastatic carcinoma, but can also be used to reveal the biological characteristics of the tumors by functional imaging.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Neoplasms, Unknown Primary / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Female. Follow-Up Studies. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173915.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


86. Matsuda M, Amemiya H, Kono H, Suzuki T, Chang MS, Izawa S, Furuya S, Takano A, Matsumoto Y, Fujii H: A huge primary peritoneal papillary adenocarcinoma which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor: report of a case. Surg Today; 2005;35(2):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A huge primary peritoneal papillary adenocarcinoma which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor: report of a case.
  • We herein report a 69-year-old woman who presented with a huge intra-abdominal tumor which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor, but turned out to be primary peritoneal papillary adenocarcinoma.
  • A fine-needle aspiration biopsy of the tumor showed poorly differentiated adenocarcinoma of unknown origin.
  • Histological and immunohistochemical examinations demonstrated the tumor to be primary peritoneal papillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / radiography. Liver Neoplasms / radiography. Peritoneal Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674505.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


87. Hayashi Y, Nishida T, Kondo J, Yamamoto K, Iijima H, Tsutsui S, Hiramatsu N, Tsujii M, Tsuji S, Ito H, Takehara T, Hayashi N: [Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease]. Nihon Shokakibyo Gakkai Zasshi; 2009 Jan;106(1):69-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease].
  • Primary lesion was not detected by the surveillance of whole gastro-intestinal tract.
  • Liver tumor biopsy samples were histologicaly analyzed and were diagnosed as adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Crohn Disease / complications. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Unknown Primary / drug therapy

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122424.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Number-of-references] 19
  •  go-up   go-down


88. Park SY, Kim BH, Kim JH, Lee S, Kang GH: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med; 2007 Oct;131(10):1561-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
  • CONTEXT: Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult.
  • Because none of the individual immunohistochemical markers used for tissue identification are both site specific and site sensitive, multiple markers are needed to improve the prediction of primary sites.
  • OBJECTIVE: To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin.
  • DESIGN: Expression profiles of CDX2, cytokeratin (CK) 7, CK20, thyroid transcription factor 1 (TTF-1), carcinoembryonic antigen (CEA), MUC2, MUC5AC, SMAD4, estrogen receptor (ER), and gross cystic disease fluid protein 15 (GCDFP-15) were generated in adenocarcinomas from 7 primary sites, followed by construction of a decision tree and design of multiple-marker panels.
  • Expression of these markers was evaluated immunohistochemically in 314 primary adenocarcinomas (50 cases each of colorectal, gastric, lung, pancreatic, bile duct, and breast, and 14 cases of ovarian origin) using the tissue array method.
  • Results were validated using 60 cases of metastatic adenocarcinoma with known primaries.
  • RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.
  • CONCLUSIONS: Determination of tissue-specific immunostaining profiles is valuable in the diagnostic differentiation of metastatic adenocarcinomas from seven common primary sites and should help to correctly predict the organ of primary tumor origin.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Immunoenzyme Techniques / methods. Neoplasm Proteins / analysis
  • [MeSH-minor] Decision Trees. Female. Humans. Neoplasms, Unknown Primary / chemistry. Neoplasms, Unknown Primary / diagnosis. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922593.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


89. Tischoff I, Tannapfel A: [Pathologic and anatomic evidence of peritoneal metastases]. Chirurg; 2007 Dec;78(12):1085-6, 1088-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumours originating in the peritoneum such as malignant peritoneal mesothelioma, primary peritoneal carcinoma, and benign peritoneal tumours along with inflammatory and reactive lesions must be differentiated from peritoneal metastases.
  • Especially in cancer of unknown primary tumour, the discrimination between primary peritoneal tumours and peritoneal metastases is difficult and often requires immunohistochemical identification.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoma / pathology. Carcinoma / secondary. Carcinoma / surgery. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Mucinous / surgery. Diagnosis, Differential. Female. Humans. Male. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritonitis / pathology. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030433.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Yu DC, Grabowski MJ, Kozakewich HP, Perez-Atayde AR, Voss SD, Shamberger RC, Weldon CB: Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg; 2010 Jun;45(6):1090-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lung tumors in children and adolescents: a 90-year experience.
  • PURPOSE: Primary lung tumors in children are rare.
  • The incidence of these lesions and their outcomes are still largely unknown.
  • This study aims to determine the incidence of different primary lung tumors in children and to contribute data leading to the development of evidence-based treatment models.
  • Patients were included if they had primary, nonhematologic lung tumors.
  • Rare pediatric lung tumors including small cell carcinoma, adenocarcinoma, and pulmonary capillary hemangiomatosis were also seen.
  • CONCLUSIONS: Primary lung tumors in children are rare and histopathologically diverse.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20620301.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Hoque MO, Soria JC, Woo J, Lee T, Lee J, Jang SJ, Upadhyay S, Trink B, Monitto C, Desmaze C, Mao L, Sidransky D, Moon C: Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol; 2006 Apr;168(4):1345-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most tumors have been shown to exhibit high vascular permeability and interstitial fluid pressure, but the transport pathways for water within tumors remain unknown.
  • We next examined the distribution of the AQP1 protein in several types of primary lung tumors (16 squamous cell carcinomas, 21 adenocarcinomas, and 7 bronchoalveolar carcinomas) by immunohistochemical staining.
  • AQP1 was overexpressed in 62% (13 of 21) and 75% (6 of 8) of adenocarcinoma and bronchoalveolar carcinoma, respectively, whereas all cases of squamous cell carcinoma and normal lung tissue were negative.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Br J Haematol. 2001 May;113(2):415-21 [11380407.001]
  • [Cites] Br J Cancer. 2002 Sep 9;87(6):621-3 [12237771.001]
  • [Cites] Gut. 2003 Jul;52(7):1008-16 [12801959.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6699-703 [14555983.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Mar;286(3):C529-37 [14592814.001]
  • [Cites] Am J Hematol. 2004 Mar;75(3):128-33 [14978691.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15772-8 [8340403.001]
  • [Cites] Am J Physiol. 1993 Oct;265(4 Pt 2):F463-76 [7694481.001]
  • [Cites] Methods Enzymol. 1995;255:395-412 [8524126.001]
  • [Cites] Genomics. 1995 Nov 20;30(2):354-7 [8586439.001]
  • [Cites] J Urol. 1996 Jul;156(1):291-5 [8648826.001]
  • [Cites] Annu Rev Physiol. 1996;58:619-48 [8815812.001]
  • [Cites] Am J Physiol. 1996 Jan;270(1 Pt 1):C12-30 [8772426.001]
  • [Cites] Nature. 1997 Jun 5;387(6633):627-30 [9177354.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 1):C1562-70 [9374641.001]
  • [Cites] J Struct Biol. 1998;121(2):191-206 [9615438.001]
  • [Cites] Am J Med Sci. 1998 Nov;316(5):310-20 [9822113.001]
  • [Cites] J Physiol. 1999 Jun 1;517 ( Pt 2):317-26 [10332084.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1149-58 [15809704.001]
  • [Cites] Nature. 2005 Apr 7;434(7034):786-92 [15815633.001]
  • [CommentIn] Am J Pathol. 2012 Sep;181(3):1112 [22901756.001]
  • (PMID = 16565507.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA096784; United States / NCI NIH HHS / CA / P30 CA16620; United States / NCI NIH HHS / CA / P50 CA96784-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 146410-94-8 / Aquaporin 1
  • [Other-IDs] NLM/ PMC1606549
  •  go-up   go-down


92. Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR: Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol; 2007 Jun;60(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
  • PURPOSE: In this study, we determine the prevalence and the prognostic value of the class III beta-tubulin microtubule protein examined immunohistochemically, in tumors of 40 patients with carcinomas of unknown primary site treated with paclitaxel-based chemotherapy.
  • CONCLUSIONS: These findings suggest that a high level of expression of class III beta-tubulin in tumor cells is associated with resistance to paclitaxel and decreased survival in patients with carcinomas of unknown primary receiving paclitaxel-based chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Biomarkers / analysis. Neoplasms, Unknown Primary / drug therapy. Paclitaxel / therapeutic use. Tubulin / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17021819.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers; 0 / TUBB3 protein, human; 0 / Tubulin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


93. Kang JJ, Eaton MS, Ma Y, Streeter O, Kumar P: Mucosa-associated lymphoid tissue lymphoma and concurrent adenocarcinoma of the prostate. Rare Tumors; 2010;2(3):e54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue lymphoma and concurrent adenocarcinoma of the prostate.
  • Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the prostate is a rare disease that characteristically follows an indolent course.
  • It is believed that infection or chronic inflammation may be triggers for malignant transformation in the prostate, but it is of unknown etiology.
  • Reports of MALT lymphomas of the prostate with other concurrent primary prostate cancers are even more limited.
  • We present the unique case of a 67-year-old male with concurrent adenocarcinoma of the prostate and primary MALT lymphoma of the prostate.
  • The patient was treated with standard therapy for prostate adenocarcinoma, which would also treat a primary MALT lymphoma.
  • He has been disease-free for over one year for both his primary malignancies.
  • This case confirms that MALT lymphoma can arise concurrently with adenocarcinoma of the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139969.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994529
  • [Keywords] NOTNLM ; MALT / prostate cancer / prostate lymphoma
  •  go-up   go-down


94. Bourke JL, Langer SW, Jensen HL: Metastasizing malignant pleomorphic adenoma in a young man. APMIS; 2007 Jul;115(7):866-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a younger man with metastasizing carcinoma of unknown primary site, where autopsy revealed a malignant pleomorphic adenoma (MPA) of the submandibular gland.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Pleomorphic / diagnosis. Bone Neoplasms / radionuclide imaging. Submandibular Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614856.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


95. Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer; 2007 Sep;43(14):2026-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Switching benchmarks in cancer of unknown primary: from autopsy to microarray.
  • INTRODUCTION: Cancer of unknown primary (CUP) is associated with unknown biology and dismal prognosis.
  • Information on the primary site of origin is scant and has never been analysed.
  • We systematically reviewed all published evidence on the CUP primary site identified by two different approaches, either autopsy or microarray gene expression profiling.
  • METHODS: Published reports on identification of CUP primary site by autopsy or microarray-based multigene expression platforms were retrieved and analysed for year of publication, primary site, patient age, gender, histology, rate of primary identification, manifestations and metastatic deposits, microarray chip technology, training and validation sets, mathematical modelling, classification accuracy and number of classifying genes.
  • RESULTS: From 1944 to 2000, a total of 884 CUP patients (66% males) underwent autopsy in 12 studies after presenting with metastatic or systemic symptoms and succumbing to their disease.
  • A primary was identified in 644 (73%) of them, mostly in the lung (27%), pancreas (24%), hepatobiliary tree (8%), kidneys (8%), bowel, genital system and stomach, as a small focus of adenocarcinoma or poorly differentiated carcinoma.
  • Four studies using microarray technology profiled more than 500 CUP cases using classifier set of genes (ranging from 10 to 495) and reported strikingly dissimilar frequencies of assigned primary sites (lung 11.5%, pancreas 12.5%, bowel 12%, breast 15%, hepatobiliary tree 8%, kidneys 6%, genital system 9%, bladder 5%) in 75-90% of the cases.
  • CONCLUSIONS: Evolution in medical imaging technology, diet and lifestyle habits probably account for changing epidemiology of CUP primaries in autopsies.
  • Discrepant assignment of primary sites by microarrays may be due to the presence of 'sanctuary sites' in autopsies, molecular misclassification and the postulated presence of a pro-metastatic genetic signature.
  • In view of the absence of patient therapeutic or prognostic benefit with primary identification, gene expression profiling should be re-orientated towards unraveling the complex pathophysiology of metastases.
  • [MeSH-major] Microarray Analysis / methods. Neoplasms, Unknown Primary / diagnosis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698346.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Ramljak V, Sarcević B, Vrdoljak DV, Kelcec IB, Agai M, Ostović KT: Fine needle aspiration cytology in diagnosing rare breast carcinoma--two case reports. Coll Antropol; 2010 Mar;34(1):201-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • First case, sebaceous carcinoma, is still quite unknown regarding its morphological characteristics and biological behavior.
  • In the second case, squamous carcinoma, also very rare, was found in a patient who previously had a number of diagnosed head and neck skin carcinomas, and was diagnosed as primary squamous breast carcinoma.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432752.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


97. Brouwer J, Senft A, de Bree R, Comans EF, Golding RP, Castelijns JA, Hoekstra OS, Leemans CR: Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol; 2006 Mar;42(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The detection of distant metastases and second primary tumours at the time of initial evaluation changes the prognosis and influences the selection of treatment modality in patients with HNSCC.
  • In this observational cohort study we prospectively compared the yield of whole body (18)FDG-PET and chest CT to detect distant metastases and synchronous primary tumours.
  • Four patients were diagnosed with distant metastases or second primary tumours: CT as well as (18)FDG-PET identified one patient with lung metastases and another with primary lung cancer.
  • In addition, (18)FDG-PET detected second primary tumours in two patients (hepatocellular carcinoma and abdominal adenocarcinoma).
  • The added value of whole body (18)FDG-PET versus chest CT was to identify unknown malignancy in 6% of the patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / radionuclide imaging. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266820.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Destombe C, Botton E, Le Gal G, Roudaut A, Jousse-Joulin S, Devauchelle-Pensec V, Saraux A: Investigations for bone metastasis from an unknown primary. Joint Bone Spine; 2007 Jan;74(1):85-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigations for bone metastasis from an unknown primary.
  • OBJECTIVES: To evaluate the respective contributions of various investigations used to identify the primary tumor in a cohort of patients referred for diagnostic evaluation of one or more bone metastases.
  • METHODS: A single-center retrospective study was conducted in a cohort of patients admitted between October 1990 and January 2000 for evaluation of one or more bone metastases with no known primary.
  • The primary was located in the lung in 37 patients, prostate in 26, breast or female genital tract in 24, urinary system in 11, gastrointestinal tract in 11, head and neck in 6, and other organs in 4.
  • In 33 patients, no primary was identified.
  • The histological biopsy findings indicated adenocarcinoma in 58 cases, epidermoid carcinoma in 28 cases, undifferentiated carcinoma in 2 cases, and other histological patterns in 9 cases.
  • Tumor marker assays were of limited value for determining the site of the primary, with the exception of prostate-specific antigen.
  • CONCLUSION: Bone biopsies performed by rheumatologists, generally under fluoroscopic guidance, usually indicate the site of the primary or at least the histological type.
  • Tumor markers are often positive but are of limited usefulness for identifying the primary.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Biopsy. Bone and Bones / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Cohort Studies. Diagnostic Imaging. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Joint Bone Spine. 2008 Jan;75(1):100; author reply 100-1 [18083617.001]
  • (PMID = 17218141.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M: C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res; 2006 Jul-Aug;26(4B):2909-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The genetic events involved in gastric cancer, the third most frequent cancer in the world with a high incidence in Pard State, Brazil, remain largely unknown.
  • MATERIALS AND METHODS: Twenty-one primary gastric adenocarcinomas were investigated by comparative genomic hybridization (CGH) and the relationships between genomic abnormalities and histopathological features were evaluated.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886612.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


100. Lehman CD, DeMartini W, Anderson BO, Edge SB: Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw; 2009 Feb;7(2):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the guidelines indicate that breast MRI may be used for patients with axillary nodal adenocarcinoma to identify the primary malignancy.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Axilla. Biopsy, Needle. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Female. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Unknown Primary / pathology. Practice Guidelines as Topic. Sensitivity and Specificity. Surgery, Computer-Assisted

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200417.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down






Advertisement